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Abstract 
With increased understanding of their roles in signal transduction and metabolism, 
eicosanoids have emerged as important players in human health and disease. Mammalian 
prostanoids and related lipid mediators perform varied functions in different tissues and organs. 
Synthesized through the oxygenation of C20 polyunsaturated fatty acids, mammalian 
eicosanoids are both pro- and anti-inflammatory. The physiological contexts in which eicosanoid 
family members act at the cellular level are not well understood. In this study, we examined 
whether the genome of Drosophila melanogaster, a powerful model for innate immunity and 
inflammation, codes for the enzymes required for eicosanoid biosynthesis. We report the 
existence of putative eicosanoid biosynthesis enzymes in Drosophila melanogaster which may 
function together as a pathway similar to the mammalian eicosanoid synthesis pathway. Standard 
sequence-based search methods failed to identify high confidence orthologs for a majority of the 
mammalian eicosanoid synthesis enzymes in D. melanogaster, and in insects generally. Using 
sensitive sequence analysis techniques, we identified candidate orthologs in the Drosophila 
genome that share low global sequence identities with their human counterparts. The Drosophila 
sequences were further scrutinized by modeling and structural analyses. We generated and 
evaluated full-length models for top-scoring Drosophila candidates corresponding to each human 
eicosanoid synthesis enzyme and identified potentially equivalent functional residues. This 
combination of sensitive sequence and structural analyses revealed that the existence of eight 
high confidence, five mid-range and eight low confidence candidates. Four predicted 
cyclooxygenases and two potential lipoxygenase activating proteins, highly divergent from their 
human counterparts, were identified, although similar methods failed to identify putative 
lipoxygenase enzymes.  Tertiary structures of a majority of identified candidate fly proteins are 
very similar to the corresponding human target enzymes and appear to possess the necessary 
v 
catalytic residues. These results, in combination with other recent biochemical studies alluding to 
eicosanoid activity in insects by other groups, suggest that D. melanogaster may indeed possess 
biosynthesis pathways for eicosanoid or eicosanoid-like biolipids.  However, the predominant 
view in the field is that an eicosanoid synthesis pathway does not exist in Drosophila primarily 
because to date clear homologs of the enzymes of this pathway have not been identified. Our 
study challenges this currently held view. Molecular-genetic and biochemical analyses of 
individual biosynthetic enzymes in D. melanogaster, a model organism with low genetic 
redundancy will reveal if the fly enzymes are functionally equivalent to their mammalian 
counterparts; their in vivo interactions will allow construction of pathways and networks in a 
physiological context. Our findings predict that classical or novel eicosanoids or eicosanoid-like 
lipid mediators regulate biological functions in insects. Eicosanoids are known to play important 
roles in insect immunity. The identification of these lipid mediators will therefore provide new 
insect control measures or the means of improving the health of beneficial insects.  
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Chapter 1: Introduction 
Overview of the eicosanoid biosynthesis pathway 
The eicosanoids are a family of biologically active lipids that have been implicated in 
various signaling pathways, with a central role as mediators of inflammation [1-3]. The 
canonical eicosanoid biosynthesis pathway begins with the release of fatty acids, primarily 
arachidonic acid (AA), from membrane phospholipids in response to activation of phospholipase 
A2 [4, 5]. At this point the canonical pathway diverges, depending on whether the fatty acid 
substrate is processed by a cyclooxygenase (COX), lipoxygenase (LOX) or a P450 epoxygenase 
(P450E). The COX enzymes generate prostanoids (prostaglandins, prostacyclins and 
thromboxanes) and resolvins, whereas the LOX enzymes produce the leukotrienes, 
hydroperoxyeicosatetraenoic acids (HPETEs), hydroxyeicosatetraenoic acids (HETEs) and 
lipoxins. There is some cross-talk between the COX and LOX pathways, as both are known to 
produce hydroxyoctadecadienoic acids (HODEs) The P450 epoxygenase pathway yields 
epoxyeicosatrienoic acids (EETs). All these downstream products of the canonical eicosanoid 
pathway branches regulate a diverse variety of signaling pathways, with the COX and LOX 
subfamilies emerging as important mediators of inflammation and immunity in mammals [6-9].  
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FIG. 1. The canonical human eicosanoid synthesis pathway. Prostaglandins are highlighted 
in red, leukotrienes in green and thromboxanes in blue. HETE mediators, which form part 
of the non-classic eicosanoid pathway, are highlighted in yellow. 
 
The COX branch of the eicosanoid pathway 
The COX and LOX branches of the eicosanoid pathway are well-characterized in 
humans. The COX enzymes (prostaglandin G/H synthases) are encoded by two genes: COX-1 
(PTGS1) and COX-2 (PTGS2) [10]. COX-1 is constitutively expressed at a low level by most 
cells. In contrast, COX-2 is upregulated at sites of inflammation and during tumor progression 
[10, 11]. COX-1 and COX-2 are membrane-associated heme-containing homodimers that 
catalyze the conversion of an 18-22 carbon polyunsaturated fatty acid (typically AA, an ω-6, 20-
carbon fatty acid) into prostaglandins G2 and H2 [12]. Although AA is the preferred substrate, 
and COX signaling tends to be pro-inflammatory, the COX enzymes are also known to 
oxygenate eicosapentaenoic acid (EPA, 20:5 n-3), linoleic acid (LA, 18:2 n-6), dihomo-γ-
linolenic acid (DHLA) and docosahexaenoic acid (DHA), with varying efficiencies [12-14]. This 
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initial substrate choice is significant, as it determines whether the downstream prostanoid will be 
pro- or anti-inflammatory. Fatty acid with two double bonds (e.g., AA) are converted into series-
2 prostanoids (e.g., PGH2, PGE2), which are associated with pro-inflammatory signaling. In 
contrast, fatty acid substrates with three or four double bonds (e.g., EPA, DHLA, respectively) 
yield series-1 and 3 prostanoids (PGH1, PGE3), which are associated with anti-inflammatory 
signaling. Anti-inflammatory resolvins are produced from EPA and DHA, whereas the pro- and 
anti-inflammatory 9- and 13-HODEs are generated from LA by COX enzymes [15,16]. 
 Non-steroidal anti-inflammatory drugs (NSAIDs) can inhibit the ability of COX enzymes to 
generate pro-inflammatory downstream products [17]. PGH2 is subsequently converted to a 
variety of downstream eicosanoids, including PGD2, PGE2, PGF1α PGF2α, PGI2 (prostacyclin), 
and the thromboxanes TXA2 and TXB2. The downstream processing route depends on the 
enzymatic machinery present in a given cell type. For example, endothelial cells primarily 
produce PGI2, whereas platelets mainly produce TXA2 [18].  
The LOX branch of the eicosanoid pathway 
The LOX pathway operates independently from the COX pathway, diverging at the 
initial fatty acid processing stage. In humans, LOX enzymes are encoded by several genes 
(ALOX5, ALOX12, ALOX12B, ALOX15). Mammalian LOX enzymes catalyze the 
stereospecific dehydrogenation and dioxygenation of a polyunsaturated fatty acid (PUFA), 
leading to the formation of a hydroxyperoxide containing a 1-hydroxyperoxy-2-trans-4-cis-
pentadiene fragment [19, 20]. The mammalian LOXs have been named according to the position 
of the carbon at which the oxygen molecule is inserted into AA, the primary fatty acid substrate, 
e.g., as 5-, 12-, or 15-LOX) [21]. The primary products are 5S-, 12S-, or 15S-HPETE, which can 
be further reduced by glutathione peroxidase to hydroxy forms (5-, 12-, 15-HETE), respectively 
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[21, 23]. 5-LOX is the only LOX that produces leukotrienes, and it is notable that its catalytic 
activity requires the presence of a second protein referred to alternatively as Arachidonate 5-
Lipoxygenase Activating Protein (ALOX5AP) or Five-Lipoxygenase Activating Protein (FLAP), 
though the precise function of FLAP is unknown at this time [19, 22]. Following the conversion 
of a fatty acid (e.g., AA) into 5-HPETE, processing by 5-LOX and other downstream leukotriene 
syntheses enzymes results in the formation of leukotrienes LTB4, LTC4, LTD4, and LTE4. The 
leukotrienes are clinically significant, as they are implicated in the allergic response and 
maintenance of chronic inflammation. 15-LOX (and to a lesser extent 5-LOX) produce the 
lipoxins LXA and LXB [23]. 
Non-classic Eicosanoids 
The cyclooxygenase and lipoxygenase branches of the eicosanoid synthesis pathway have 
been thoroughly studied in human and other mammalian systems. As a result, the major end 
products of these pathways (i.e., prostaglandins, thromboxanes and leukotrienes) are referred to 
as canonical eicosanoids. However, in recent years additional classes of oxygenated PUFA 
derivatives have been identified as minor or alternative products of the eicosanoid synthesis 
pathways, including eoxins, hepoxilins, resolvins, lipoxins, epi-lipoxins, levuglandins, 
oxoeicosanoids, hydroxyeicosatrienoic acids (HETEs), epoxyeicosatrienoic acids (EETs) and 
endocannabinoids. Together, this group represents a large and growing family of lipid mediators 
generally referred to as non-classic eicosanoids. 
Eoxins are pro-inflammatory eicosanoids derived from arachidonic acid by arachidonate 15-
lipoxygenase (ALOX15) [24]. The eoxins derive their name from eosinophils, the cell type in 
which they were originally discovered in abundance [25]. Eoxins resemble the cysteinyl 
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leukotrienes produced by ALOX5 but have a different three-dimensional structure (i.e., eoxins 
are 14,15-leukotriene analogs) and are generated by cells in response to different stimuli [26]. 
Hepoxilins are hydroxy-epoxy eicosanoids (epoxyalcohols) which contain both hydroxyl 
and epoxy groups, the latter spanning the C11-C12 double bond, and unlike leukotrienes and 
lipoxins, none of the double bonds are conjugated [27]. Hepoxilins are produced by the 
epidermal subfamily of mammalian lipoxygenase enzymes ALOX12B and ALOXE3 (12-R-
LOX and eLOX-3, respectively), which are preferentially expressed in the skin and several other 
epithelial tissues [28]. These enzymes act in concert to convert fatty acid substrates via R-
HPETEs to specific epoxyalcohol derivatives [29]. 12R-LOX and eLOX-3 are unique compared 
to all other currently identified LOXs in that 12R-LOX is the only mammalian LOX that forms 
products with R-chirality and eLOX-3 functions as a hydroperoxide isomerase by exhibiting only 
latent dioxygenase activity [30].  
Lipoxins, epi-lipoxins and resolvins are potent anti-inflammatory eicosanoids which 
modulate the inflammation response in mammals. Lipoxins and epi-lipoxins (stereoisomers of 
lipoxins) are derived from arachidonic acid and contain three hydroxyl residues and four double 
bonds [31]. Lipoxins synthesis typically involves a LOX enzyme which adds a 15S-hydroxyl 
residue to arachidonic acid, whereas synthesis of the epi-lipoxins involves aspirin-pretreated 
COX-2 or a CYP450 enzyme capable of adding a 15R-hydroxyl residue to arachidonic acid [32]. 
Resolvins are a structurally diverse class of oxygenated derivatives of the omega-3 PUFAs 
(EPA, DHA, DPA), which derive their name from the fact that this family of lipid mediators is 
known to be produced during the resolution phase of the inflammation response [33, 34]. 
Levuglandins are reactive γ-ketoaldehydes formed by the spontaneous rearrangement of 
prostaglandin H (PGH) [35, 36]. Levuglandins are highly effective at cross-linking proteins and 
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DNA, which makes detection difficult as newly-produced levuglandins are rapidly sequestered 
by available nucleophiles, potentially generating heterogeneous protein aggregates which may 
have pathologic consequences if prostanoids are aberrantly overexpressed [35]. 
Oxo-eicosanoids refer to oxygenated derivatives of eicosatetraenoic acid (e.g., 5-Oxo-
6,8,11,14-eicosatetraenoic acid, “5-oxo-ETE”), which are produced by a dehydrogenase acting 
on HETE intermediates produced by LOX enzymes [37]. Oxo-eicosanoids are known to produce 
pro-inflammatory effects similar to leukotrienes, but interact with different cell surface receptors 
[38, 39]. 
Epoxyeicosatrienoic acids (EETs) and hydroxyeicosatrienoic acids (HETEs) are derived 
from arachidonic acid by a subset of CYP450 enzymes [40]. The CYP450 superfamily includes 
various heme-containing enzymes that are essential for basic metabolism in humans and 
ubiquitous among all five kingdoms of life [41]. In the context of eicosanoid synthesis, CYP450 
enzymes are necessary for the synthesis of prostacyclins and thromboxanes (i.e., prostacyclin 
synthase and thromboxane A synthase are both CYP450 family members) [42]. However, 
CYP450 enzymes are further relevant to arachidonic acid metabolism given that two distinct 
subfamilies (ω-hydroxylases and epoxygenases) are also able to form metabolites derived from 
arachidonic acid [40, 43, 44]. Arachidonic acid is metabolized by the CYP450 ω-hydroxylase 
family of enzymes in mammalian cells to 7-, 10-, 12-, 13-, 15-, 16-, 17-, 18-, 19-, and 20-
HETEs, with the pro-inflammatory 20-HETE being the primary metabolite [45]. In contrast, the 
epoxygenase CYP450 enzymes metabolize arachidonic acid by olefin epoxidation, resulting in 
four regioisomeric epoxyeicosatrienoic acids (EETs): 5,6-EET, 8,9-EET, 11,12-EET, and 14,15-
EET [46]. Each of these regioisomers can be formed as either an R,S or S,R enantiomer given 
that the epoxide group can attach to the double bonds in two separate configurations [47]. 
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CYP450 enzymes also convert EPA into epoxy-derivatives, and endocannabinoids containing 
11,12- and 14,15-EETs. [48]. 
The various non-classic eicosanoids discussed above includes clinically important 
autocrine and paracrine mediators of inflammation and homeostasis that operate in parallel with 
the classic eicosanoids.  
Eicosanoid biosynthesis and signaling in insects 
 Extensive scientific literature from the last 25 years, based primarily in mammalian cell 
culture and rodent models, has established the central roles of eicosanoids in the response to 
infection (acute inflammation) as well as in chronic diseases in humans and various animal 
models [47-49]. A number of vertebrate and cell culture models that mimic human diseases are 
now available for studying inflammation. Despite an overwhelming increase in our knowledge 
regarding mechanisms underlying inflammation, it has been difficult to genetically map the 
signaling pathways targeted by eicosanoids. A primary reason for this gap is the large number of 
prostanoids and lipid mediators and the complexity of the mammalian system itself.  
In order to better understand the COX and LOX pathways, identification of suitable model 
organisms is a priority. The COX family enzymes are highly conserved across the animal 
kingdom, with orthologs found in the primitive marine corals as well as the higher vertebrates 
[50]. Traditional genomic analyses have failed to identify COX orthologs in the known genomes 
of insects, unicellular organisms, or plants, although prostaglandins, their primary products, have 
been found in some of these organisms [51, 52].  Recent studies have suggested that an insect 
cyclooxygenase may exist in orthologs of the gene Pxt [53, 54]. LOX enzymes display an even 
broader degree of conservation, with orthologs found across the animal kingdom and in a variety 
of plants [55]. Interestingly enough, sequence and biochemical analyses have failed to identify 
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any insect LOX orthologs, with the sole exception being a report of LOX activity in the primitive 
insect, Thermobia domestica [56]. 
As mediators of the immune and inflammatory response in mammals, eicosanoids remain 
an important area of research. A better understanding of these enzymes (and their biosynthesis), 
may yield therapeutics that mitigate inflammation or compensate for defects in the immune 
response. The canonical eicosanoid synthesis pathway (prostanoids and leukotrienes) is well-
characterized in humans and in mammalian models. However, researchers would benefit from 
having access to a low cost, high volume model to study this pathway, i.e., D. melanogaster. In 
order to better understand the in vivo roles of mammalian COX and LOX pathways, we 
examined if enzymes of these pathways are encoded in the Drosophila genome. Flies do not 
produce C20 PUFAs, but nevertheless possess the ability to produce lipid mediators [57].  While 
an initial BLAST searches based on sequence analysis alone failed to identify likely fly orthologs 
for these enzymes, a more rigorous approach using iterative sequence searches combined with 
structural modeling revealed a surprising degree of similarity and apparent conservation of 
catalytic as well as other key functional residues. Our study suggests that insects possess a 
functional eicosanoid pathway and open up possibilities of utilizing a powerful model organism 
for eicosanoid research. 
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Chapter 2: Materials and Methods 
Overview 
The flowchart provided below summarizes the general protocol of the present study with 
the various tools used to identify and characterize putative D. melanogaster eicosanoid synthesis 
enzymes which may be orthologs for the classic eicosanoid synthesis enzymes discussed in detail 
below. 
 
FIG. 2. Summary of the workflow and tools used to carry out the present study. 
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Selection and Characterization of Human Eicosanoid Synthesis Enzymes 
A canonical eicosanoid synthesis pathway in humans was obtained from the NCBI 
BioSystems Database by compiling enzymes identified in the Eicosanoid Synthesis (BSID: 
198888) and Arachidonic Acid pathway maps (BSID: 829971) [58]. Protein sequence(s) for each 
gene associated with the canonical human eicosanoid synthesis pathway were obtained from the 
NCBI RefSeq database [59]. In each case, either the sole protein product or the major isoform 
was selected as the representative sequence for each enzyme. Known and high-confidence 
predicted orthologs for each of the canonical mammalian eicosanoid synthesis enzymes were 
identified using the KEGG Orthology database [60]. A multiple sequence alignment (MSA) for 
each target enzyme with the selected orthologs was then generated using PROMALS3D, 
followed by manual refinement of the alignment [61]. Domains and active sites on each query 
and putative D. melanogaster ortholog enzyme were annotated (or predicted, in the case of the 
putative orthologs) using the Pfam and InterPro databases [62, 63]. Consensus secondary 
structure profiles were generated using the PsiPred, JPred and PSSPred servers [64-66] to 
confirm identified functional domains and to ascertain domain boundaries. The mammalian 
eicosanoid synthesis enzymes selected as targets for this study are summarized by Table 1. 
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TABLE 1. Summary of the mammalian eicosanoid synthesis enzymes selected as 
representatives for this study.  
 
TABLE 1: Human Eicosanoid Synthesis Enzymes 
NCBI Gene 
Accession 
(UniProt ID) 
NCBI Protein 
RefSeq Accession 
(length) 
Common Name 
Representative 
Crystal 
Structure  
ALOX5 
(P09917) 
NP_000689.1 
(674 aa) 
Arachidonate 5-
lipoxygenase 
3O8Y 
(2.39 Å) 
ALOX12 
(P18054) 
NP_000688.2 
(663 aa) 
Arachidonate 12-
lipoxygenase, S-type 
3D3L 
(2.60 Å) 
ALOX12B 
(O75342) 
NP_001130.1 
(701 aa) 
Arachidonate 12R-
lipoxygenase, R-type 
None available. 
ALOX15 
(P16050) 
NP_001131.3 
(662 aa) 
Arachidonate 15-
lipoxygenase 
2P0M 
(2.40 Å) 
ALOX5AP 
(P20292) 
NP_001620.2 
(161 aa) 
Arachidonate 5-
lipoxygenase Activating 
Protein 
2Q7M 
(4.00 Å) 
LTA4H 
(P09960) 
NP_000886.1 
(611 aa) 
Leukotriene A4 hydrolase 
3CHO 
(1.80 Å) 
LTC4S 
(Q168730 
NP_665874.1 
(150 aa) 
Leukotriene C4 synthase 
3PCV 
(1.90 Å) 
GGT1 
(P19440) 
NP_001275762.1 
(569 aa) 
Leukotriene C4 hydrolase 
4GDX 
(1.67 Å) 
DPEP1 
(P16444) 
NP_001121613.1 
(411 aa) 
Dipeptidase 1 
1ITQ 
(2.30 Å) 
PTGS1 
(P23219) 
NP_000953.2 
(599 aa) 
Cyclooxygenase 1 
1Q4G 
(2.00 Å) 
PTGS2 
(P35354) 
NP_000954.1 
(604 aa) 
Cyclooxygenase 2 
3NT1 
(1.73 Å) 
PTGDS 
(P41222) 
NP_000945.3 
(190 aa) 
Prostaglandin D synthase 
4IMO 
(1.88 Å) 
PTGIS 
(Q16647) 
NP_000952.1 
(500 aa) 
Prostacyclin synthase 
2IAG 
(2.15 Å) 
PTGES 
(O14684) 
NP_004869.1 
(152 aa) 
Microsomal prostaglandin 
E synthase 1 
4AL0 
(1.16 Å) 
PTGES2 
(Q9H7Z7) 
NP_079348.1 
(377 aa) 
Microsomal prostaglandin 
E synthase 2 
2PBJ 
(2.80 Å) 
PTGES3 
(Q15185) 
NP_006592.3 
(160 aa) 
Cytosolic prostaglandin E 
synthase 
1EJF 
(2.49 Å) 
TBXAS1 
(P24557) 
NP_001052.2 
(534 aa) 
Thromboxane A2 synthase None available. 
AKR1C3 
(P42330) 
NP_003730.4 
(323 aa) 
Prostaglandin F synthase 
1RY0 
(1.69 Å) 
CBR1 
(P16152) 
NP_001748.1 
(277 aa) 
Carbonyl reductase 1 
3BHM 
(1.80 Å) 
HPGD 
(P15428) 
NP_000851.2 
(266 aa) 
15-hydroxyprostaglandin 
dehydrogenase NAD(+) 
2GDZ 
(1.65 Å) 
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Identification of Potential Eicosanoid Synthesis Enzymes in D. melanogaster 
We used several different sequence analysis algorithms to identify candidate Drosophila 
orthologs for each human enzyme. Specifically, each human enzyme reference sequence was 
queried against a subset of the D. melanogaster NCBI non-redundant sequence database using 
PSI-BLAST, DELTA-BLAST or JACKHMMER [67-69]. DELTA-BLAST is a more sensitive 
variant of the traditional BLAST algorithm that incorporates domain information from pre-
constructed position specific scoring matrices (PSSMs) in order to improve detection of 
homology. JACKHMMER is an alternative sequence analysis and alignment tool that relies on 
hidden Markov model (HMM) profiles in order to boost sensitivity compared to the traditional 
BLAST algorithms. JACKHMMER converts a query sequence into a HMM profile using a 
substitution matrix and gap penalties, which is then searches against a sequence database (e.g., 
the NCBI refseq database). Sequences that score above the inclusion threshold from this first 
search are then aligned and used to construct a second HMM profile, which may then be queried 
once again against the same database [70]. The iterative nature of this filtering process typically 
results in a HMM profile that is able to detect distant homologs that may not be detected by the 
traditional BLAST algorithms. For this study, BLAST and HMMer algorithms were leveraged as 
part of a combined approach in order to identify candidates which may be remote homologs for 
the human eicosanoid synthesis enzymes. 
Each search was conducted with three iterations using the default parameters. D. 
melanogaster candidates with statistically significant full-length alignments to the query were 
selected after each round. These candidates were then analyzed using the same secondary 
structure and domain analysis tools as discussed in the section above. Each candidate was then 
aligned against the previously generated MSA (containing the human enzyme and 
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known/predicted orthologs) in order to screen out hits that lacked known functional residues 
and/or those with substantially dissimilar secondary structure or domain architecture. 
In silico Modeling of D. melanogaster Candidates 
Full-length three-dimensional models were generated for each top-scoring D. 
melanogaster candidate protein identified in the previous stage using the MODELLER, 
LOMETS and I-TASSER software packages [71-73]. MODELLER, a homology modeling tool, 
predicts the tertiary structure of a protein sequence based on satisfaction of spatial restraints 
derived from sequentially similar templates whose structure is known (i.e., a sequence-sequence 
comparison). In contrast, I-TASSER utilizes a threading algorithm (i.e., a sequence-structure 
comparison) and fragment assembly based on replica-exchange Monte Carlo simulations; it also 
builds unaligned primary sequence regions using ab initio methods. LOMETS is a meta-server 
that generates and ranks modeling results produced using several alternative threading 
algorithms which are executed in parallel. The accuracy of homology modeling depends largely 
on the target-template alignment, with ≥40% sequence identity generally yielding high quality 
models and ≥30% being the lower threshold for an acceptable model [74]. However, threading 
based modeling tools are generally less sensitive to sequence identity differences and some 
packages (e.g., I-TASSER) are known to generate high quality models using templates sharing as 
little as 20-30% sequence identity with the target sequence [75, 76]. 
Each D. melanogaster candidate sequence was searched against the Protein Data Bank 
database of published structures using PSI-BLAST and JACKHMMER [67, 69]. Several 
potential templates with ≥30%, full-length sequence identity were aligned against each candidate 
using PROMALS3D and evaluated [61]. In instances where a single full-length template was 
available, MODELLER was used to generate a three-dimensional model of the candidate.  If a 
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suitable single full-length template was not found, either due to a lack of coverage or low 
sequence identity within the aligned range, I-TASSER was used to generate a composite model 
based on several templates. In each case, the initial model was used to generate a refined full 
atomic model using ModRefiner, which also optimizes sidechain placement [77]. All of the 
refined models were then evaluated using the PROCHECK, ProSa, ProQ2 and MODFOLD4 
servers [78-80]. Loops and unstructured N- and C-terminal regions in these models were 
optimized using ab initio methods (e.g., MODELLER’s loop routines or QUARK), refined using 
ModRefiner and reevaluated as necessary [81]. Unsuitable models were rejected and rebuilt 
using alternatives templates according to the preceding protocol. Models were analyzed using the 
surface property tools in the Chimera and PyMol visualization and structural modeling packages, 
in addition to online tools including, COFACTOR, and COACH [82-87].  
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Chapter 3: Results 
Identification and Characterization of Candidate Eicosanoid Synthesis Enzymes in D. 
melanogaster 
A purely sequence-based analysis of the D. melanogaster genome (Release 6.04, 
February 24th, 2015) using traditional sequence analysis tools (e.g., BLASTp) fails to identify 
likely orthologs for a majority of the canonical human eicosanoid synthesis enzymes. However, 
using a more sensitive approach based on iterative HMMER searches and structural modeling, 
we have uncovered potential candidates in D. melanogaster that may function as eicosanoid 
synthesis enzymes. This analysis is supported by the fact that a majority of these candidates 
share a highly similar tertiary structure with the human target enzymes and also appear to 
possess the necessary catalytic residues. A summary of our findings is provided as Table 2.  
TABLE 2. Summary of D. melanogaster genes encoding potential orthologs for the 
mammalian eicosanoid synthesis enzymes examined during this study. 
 
TABLE 2: Summary of Findings 
Human 
Gene 
D. melanogaster Candidate(s) 
CG 
Identifier 
Flybase 
Identifier 
PTGS1, 
PTGS2 
CG4009, isoform B CG4009 FBgn0038469 
Pxt (“Peroxinectin-like”) CG7660 FBgn0261987 
Cardinal CG6969 FBgn0263986 
PTGDS Nlaz (“Neural Lazarillo”) CG33126 FBgn0053126 
HPGDS GST S1 (“Glutathione S transferase S1”) CG8938 FBgn0010226 
PTGIS CYP450-4D2 CG3466 FBgn0011576 
PTGES 
MGST-like, isoform A (“microsomal 
glutathione S-transferase-like”) 
CG1742 FBgn0025814 
PTGES2 SupRef(2)p [“Suppressor of Ref(2)p”] CG4086 FBgn0004465 
PTGES3 CG16817, isoform A CG16817 FBgn0037728 
TBXAS1 CYP450-9H1 CG17577 FBgn0033775 
AKR1A1, 
AKR1B1, 
AKR1C3 
CG6084, isoform D CG6084 FBgn0086254 
CBR1 CBR, isoform B (“carbonyl reductase”) CG11200 FBgn0034500 
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ALOX5, 
ALOX12, 
ALOX12B, 
ALOX15 
None identified N/A N/A 
ALOX5AP CG33177 CG33177 FBgn0053177 
LTA4H CG10602 CG10602 FBgn0032721 
LTC4S CG33178, isoform A CG33178 FBgn0053178 
GGT1 
GGT, isoform A (“gamma-glutamyl 
transpeptidase”) 
CG6461 FBgn0030932 
DPEP1 CG6154, isoform C CG6154 FBgn0039420 
HPGD CG18814 CG18814 FBgn0042137 
GPX1 PHGPx, isoform A CG12013 FBgn0035438 
CPA1 CG18585, isoform A CG18585 FBgn0031929 
 
Group 1: The High Scoring Matches 
Eight of the putative orthologs identified in this search are notable for being particularly 
high confidence matches: CG1742, CG4086, CG6084, CG10602, CG6461, CG6154, CG12013 
and CG18585. Members of this set share a minimum of 30% sequence identity with the human 
enzyme, the same overall fold, and display conservation of one or more functional residues.  
Prostaglandin E Synthase (PTGES) 
The first gene in this set, CG1742 (“MGST-like, isoform A,” NP_524696.1), encodes a 
152 amino acid protein predicted to have a single pfam domain (MAPEG, PF01124) spanning 
the 18 to 148 amino acid region. This protein displays 34% identity and 53% similarity to the 
sequence of human prostaglandin E synthase (PTGES, NP_004869.1). PTGES is an integral 
membrane protein that operates as a homotrimer, and is known to catalyze the oxidoreduction of 
prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2). PTGES is also characterized 
by the presence of a single MAPEG domain, which spans the region 16-146. PTGES (e.g., PDB 
4AL0). The predicted structure of CG1742 are nearly identical and display an RMSD 1.15 Å 
when superimposed, as shown in Fig. 9 below. 
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PTGES is a glutathione-binding protein, and residues R38, R70, E77, R110, Y117, R126, and 
Y130 are associated with this activity [88]. Structural superposition reveals that CG1742 has an 
aligned match for each of these residues, R40, R71, E78, R111, Y118, R128 and F132. With 
respect to the last residues, a tyrosine to phenylalanine substitution is likely to be functionally 
equivalent as phenylalanine and tyrosine have side chains with a single aromatic ring of similar 
volume. Phenylalanine differs only in that it lacks the hydroxyl group in the ortho position on the 
benzene ring. Previous studies report that the aromatic ring of Y130 is likely important for 
PGH2-binding and an analog for this structural element is provided by F132 [89]. 
A. Predicted Secondary Structure  
 
 
FIG. 3. Predicted secondary structure of PTGES and CG1742 calculated using 
PROMALS3D. 
 
B. Domain Architecture 
 
FIG. 4. Predicted domain architecture of PTGES and CG1742 determined using Interpro 
and Pfam. 
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C. Model Generation and Validation 
 
1. Generation 
 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling 
CG1742. All three tools identify chain A of 4YL0 (human prostaglandin E synthase) as a high-
scoring match suitable for single-template modeling. 
CG1742 Range Template Range % Identity % Similarity E-Value 
4-151 2-149 36% 58% 5.3e-22 
 
 
 
FIG. 5. HMM profile of CG1742 aligned against chain A of 4YL0, a template structure 
selected for modeling CG1742. 
 
2. Validation 
The quality of the CG1742 model was evaluated using ProQ2 and ProSA. The per 
residue S-Score plot generated by ProQ2 was mapped to the CG1742 model by saving the S-
Score assigned to each residue as a B-factor field parameter and then rendering a color-coded 
ribbon view in Chimera based upon this parameter. As illustrated by the image below, overall 
model quality following refinement is high. The quality of the CG1742 model was also evaluated 
using ProSA and found to display a quality level comparable to experimentally determined 
structures having a comparable length (i.e., a global Z-score of -4.07). The ProSA per-residue 
energy score graph is also favorable, showing a score that is consistently negative over a window 
size of 40 residues. 
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FIG. 6. Validation of the CG1742 model: ProQ2 quality score mapped to a 3D model of 
CG1742 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
 
D. Structural Analyses 
A structural superposition reveals that the CG1742 model and human prostaglandin E 
synthase (4AL0) display a similar secondary structure architecture with substantial full-length 
overlap. The pairwise alignment generated by this structural superposition also indicates 
conservation of residues having similar physiochemical properties. 
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1. Secondary Structure  
 
 
FIG. 7. Pairwise alignment of CG1742 and 4AL0 generated from structural superposition 
with shared secondary structure elements and conserved residues highlighted. 
 
2. Physiochemical Properties 
 
 
FIG. 8. Pairwise alignment of CG1742 and 4AL0 generated from structural superposition 
with conserved residues highlighted using the CLUSTALX color scheme. 
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E. Analysis of Functional Residues 
PTGES (PDB: 4AL0) and CG1742 Model 
PTGES Structure 
D. melanogaster 
Model 
Superimposed 
   
FIG. 9. PTGES (4AL0, cyan-blue) superimposed on the predicted 
structure of CG1742 (green-red). RMSD: 1.015 Å. 
 
PTGES (PDB: 4AL0) and CG1742 Model Superimposed 
 
 
FIG. 10. PTGES (4AL0, cyan-blue) superimposed on the predicted structure 
of CG1742 (green-red), with potential matches for conserved functional 
residues highlighted. 
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F. Summary Table 
 
TABLE 3. Summary of features shared by PTGES and potential D. melanogaster ortholog 
CG1742. 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
Prostaglandin-E-synthase 
(PTGES, NP_004869.1, 
PDB: 4AL0) 
152 
MAPEG (PF01124) 
16-146 
R38, E77, R70, 
R110, Y117, R126, 
Y130 34% ID 
53% SIM 
1.015 Å 
MGST-like 
(CG1742, NP_524696.1) 
152 
MAPEG (PF01124) 
18-148 
R40, E78, R71, 
R111, Y118, R128, 
F132 
 
Prostaglandin Synthase E 2 (PTGES2) 
The second gene in this set, CG4086 (“Su(P) Suppressor of ref(2)P sterility,” 
NP_524116.2) encodes a 417 amino acid protein. CG4086 displays 33% identity and 49% 
similarity to the sequence of human prostaglandin E synthase 2 (PTGES2, NP_079348.1). 
PTGES2 is membrane-associated, as opposed to PTGES which is an integral membrane protein, 
though both catalyze the same reaction. Despite the functional similarities, PTGES2 possesses a 
substantially different domain architecture and tertiary structure. PTGES2 possesses GST 
domains (PF13417 and PF14497) spanning amino acids 104-175 and amino acids 201-368. 
CG4086 shares a highly similar domain architecture with a Glutaredoxin domain (PF00462), 
which is functionally related to the GST domain, spanning amino acids 125-184 and a GST 
domain (PF14497) spanning amino acids 248-396. PTGES2’s catalytic activity requires C110 
[90]. The crystal structure of truncated PTGES2 has been published (1Z9H), with the N-terminal 
membrane-associated region omitted (residues 1 to 99). Superposition of this truncated structure 
against the predicted structure of CG4086 reveals an RMSD of 0.814 Å. CG4086’s C133 
overlaps with PTGES2’s C110, suggesting a match for this catalytic residue. 
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A. Predicted Secondary Structure 
 
 
FIG. 11. Predicted secondary structure of PTGES2 and CG4086 calculated using 
PROMALS3D. 
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B. Domain Architecture 
 
FIG. 12. Predicted domain architecture of PTGES2 and CG4086 determined using 
Interpro and Pfam. 
 
C. Model Generation and Validation 
 
1. Generation 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling 
CG4086. All three tools identify chain A of 1Z9H (Macaca fascicularis prostaglandin E 
synthase-2) as a high-scoring match suitable for single-template modeling. The human and M. 
fascicularis orthologs of prostaglandin E synthase-2 are membrane-bound enzymes with a short 
N-terminal transmembrane domain. The cytosolic portion of M. fascicularis prostaglandin E 
synthase-2 begins at approximately position 80 of the full-length sequence and includes the 
remainder of the protein. The 1Z9H structure provides data for the majority of this cytosolic 
domain (i.e., 100-373) of the full-length M. fascicularis prostaglandin E synthase-2 sequence. 
The cytosolic domain of M. fascicularis prostaglandin E synthase-2 is identified as a template 
suitable for modeling 120-397 of the CG4086 sequence. The N-terminus of CG4086 is predicted 
to have a transmembrane or membrane-associated region, suggesting a similar shared 
architecture compared to human and M. fascicularis prostaglandin E synthase-2. 
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CG4086 Range Template Range % Identity % Similarity E-Value 
120-397 3-288 44% 65% 1.1e-71 
 
 
FIG. 13. HMM profile of CG4086 aligned against chain A of 1Z9H, a template structured 
selected for modeling CG4086. 
 
2. Validation 
The quality of the CG4086 model was evaluated using ProQ2 and ProSA, as described 
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score 
of -6.52). The ProSA per-residue energy score graph is also favorable, showing a score that is 
consistently negative over a window size of 40 residues. The N-terminal region of the model is 
indicated to have a comparatively low quality. However, this may be explained by the fact that 
this segment connects to the predicted transmembrane or membrane-associated N-terminal 
domain which was for which no suitable template exists at this time. The N-terminal segment 
may be a disordered linker to the membrane-bound/associated N-terminus. In any event, this 
segment cannot be reliably modeled using existing homology or ab initio methods. 
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FIG. 14. Validation of the CG4086 model: ProQ2 quality score mapped to a 3D model of 
CG4086 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
 
D. Structural Analyses 
A structural superposition reveals that the CG4086 model and M. fascicularis 
prostaglandin E synthase-2 (1Z9H) display a similar secondary structure architecture across the 
modeled region with substantial full-length overlap. The pairwise alignment generated by this 
structural superposition also indicates substantial conservation of residues having similar 
physiochemical properties. 
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1. Secondary Structure 
 
FIG. 15. Pairwise alignment of CG4086 and 1Z9H generated from structural superposition 
with shared secondary structure elements and conserved residues highlighted. 
 
1. Physiochemical Properties 
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FIG. 16. Pairwise alignment of CG4086 and 1Z9H generated from structural superposition 
with conserved residues highlighted using the CLUSTALX color scheme. 
 
E. Analysis of Functional Residues 
PTGES2 (PDB: 1Z9H) and CG4086 Model 
PTGES Structure 
D. melanogaster 
Model 
Superimposed 
 
 
 
FIG. 17. Truncated PTGES2 (1Z9H, cyan-blue) superimposed on the predicted 
structure of CG4086 (green-red). RMSD: 0.814 Å. 
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PTGES2 (PDB: 1Z9H) and CG4086 Model Superimposed 
 
FIG. 18. Truncated PTGES2 (1Z9H, cyan-blue) superimposed on the 
predicted structure of CG4086 (green-red), with potential matches for 
conserved functional residues highlighted. 
 
 
F. Summary Table 
 
TABLE 4. Summary of features shared by PTGES2 and potential D. melanogaster ortholog 
CG4086. 
 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
Prostaglandin-E-synthase 2 
(PTGES2, NP_079348.1, 
PDB: 1Z9H) 
377 
GST-N3 domain 
(PF13417) 
104-175 
 
GST-C3 (PF14497) 
201-368 
C110 
33% ID 
49% SIM 
 0.814 Å 
Suppressor of ref(2)P 
sterility 
(CG4086, NP_524116.2) 
417 
Glutaredoxin domain 
(PF00462) 
125-184 
 
GST-C domain 
(PF14497) 
248-396 
C133 
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AKR1A1 
The third gene in this set, CG6084, encodes a 316 amino acid protein that is a high 
confidence match for the human AKR1A1 [“alcohol dehydrogenase NADP(+),” NP_001619.1]. 
This enzyme, along with enzymes encoded by the related genes in this family (e.g., AKR1B5 
and AKR1C3), catalyzes the NADPH-dependent reduction of a variety of aromatic and aliphatic 
aldehydes to their corresponding alcohols. In particular, AKR1B1 and AKR1B5 are known to 
function as prostacyclin F synthases, converting prostaglandin endoperoxide H2 (PGH2) to 
prostaglandin F2α (PGF2α) [91]. CG6084 and AKR1A1 share identical domain architectures [a 
single aldo/keto reductase family (PF00248) domain], as well as 48% identity and 62% similarity 
at the sequence level. AKR1A1 function requires the presence of three residues for its catalytic 
activity, Y49, K78 and H111 [92]. CG6084 possesses analogs for this triad of residues in the 
form of Y50, K79 and H112. In addition, the structural overlap of the predicted structure for 
CG6084 and human AKR1A1 displays an RMSD of 0.847 Å. 
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A. Predicted Secondary Structure 
 
 
FIG. 19. Predicted secondary structure of AKR1A1 and CG6084 calculated using 
PROMALS3D. 
 
B. Function/Domain Analysis 
 
FIG. 20. Predicted domain architecture of AKR1A1 and CG6084 determined using 
Interpro and Pfam. 
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C. Model Generation and Validation 
 
1. Generation 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling 
CG6084. All three tools identify chain A of 2ALR (human aldehyde reductase, AKR1A1) as a 
high-scoring match suitable for single-template modeling. 
CG6084 Range Template Range % Identity % Similarity E-Value 
6-316 5-324 51% 73% 1.3e-98 
 
 
FIG. 21. HMM profile of CG6084 aligned against chain A of 2ALR, a template structure 
selected for modeling CG6084. 
 
2. Validation 
 
The quality of the CG6084 model was evaluated using ProQ2 and ProSA, as described 
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score 
33 
of -10.94). The ProSA per-residue energy score graph is also favorable, showing a score that is 
consistently negative over a window size of 40 residues.  
 
           
FIG. 22. Validation of the CG6084 model: ProQ2 quality score mapped to a 3D model of 
CG6084 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
 
D. Structural Analyses 
A structural superposition reveals that the CG6084 model and human aldehyde reductase 
(2ALR) display a similar secondary structure architecture across the modeled region with 
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substantial full-length overlap. The pairwise alignment generated by this structural superposition 
also indicates substantial conservation of residues having similar physiochemical properties. 
1. Secondary Structure 
 
FIG. 23. Pairwise alignment of CG6084 and 2ALR generated from structural superposition 
with shared secondary structure elements and conserved residues highlighted. 
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2. Physiochemical Properties 
 
 
 
FIG. 24. Pairwise alignment of CG6084 and 2ALR generated from structural superposition 
with conserved residues highlighted using the CLUSTALX color scheme. 
 
E. Analysis of Functional Residues 
AKR1A1 (PDB: 2ALR) and CG6084 Model 
AKR1A1 Structure 
D. melanogaster 
Model 
Superimposed 
    
FIG. 25. AKR1A1 (2ALR, cyan-blue) superimposed on the predicted structure of CG6084 
(green-red). RMSD: 0.847 Å. 
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AKR1A1 (PDB: 2ALR) and CG6084 Model Superimposed 
 
FIG. 26. AKR1A1 (2ALR, cyan-blue) superimposed on the predicted 
structure of CG6084 (green-red), with potential matches for conserved 
functional residues highlighted. 
 
 
F. Summary Table 
 
TABLE 5. Summary of features shared by AKR1A1 and potential D. melanogaster 
ortholog CG6084. 
 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
Prostacyclin F synthase 
(AKR1B1, NP_001619.1, 
PDB: 1RY0) 
316 
Aldo/keto reductase 
family (PF00248) 
4-289 
Y49, K78, H111 
48% ID 
62% SIM 
0.847 Å 
Uncharacterized protein 
(CG6084, NP_648484.1) 
316 
Aldo/keto reductase 
family (PF00248) 
9-282 
Y50, K79, H112 
 
LTA4H 
The fourth gene in this set, CG10602 encodes a 613 amino acid protein that displays 44% 
identity and 58% similarity to human leukotriene A4 hydrolase (LTA4H, NP_000886.1). 
LTA4H is an epoxide hydrolase that catalyzes the hydrolysis of the epoxide LTA4 to the diol, 
37 
LTB4. This catalytic activity requires the presence of a zinc ion, which is coordinated by the 
catalytic triad of H296, H300 and E319. Residues E297, D376 and Y384 are also reportedly 
essential for efficient catalysis [93]. LTA4H’s domain architecture consists of Peptidase family 
M1 (PF01433) spanning 13-387 and a Leukotriene A4 hydrolase, C-terminal domain (PF09127) 
spanning amino acids 464-608. CG10602 shares an identical domain organization as well as the 
critical residues at H293, H297, E316 (the zinc triad) and E294, D374 and Y382. The tertiary 
structure similarity is readily apparent, as evidenced by a superposition of human LTA4H 
(1H19) and the predicted stature of CG10602, which results in an RMSD of 0.891 Å. 
A. Predicted Secondary Structure 
 
 
FIG. 27. Predicted secondary structure of LTA4H and CG10602 calculated using 
PROMALS3D. 
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B. Domain Architecture 
 
FIG. 28. Predicted domain architecture of LTA4H and CG10602 determined using 
Interpro and Pfam. 
 
C. Model Generation and Validation 
 
1. Generation 
 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling 
CG10602. All three tools identify chain X of 3B7U (human leukotriene A4 hydrolase) as a high-
scoring match suitable for single-template modeling.  
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CG10602 Range Template Range % Identity % Similarity E-Value 
6-611 9-614 45% 66% 4.1e-164 
 
 
FIG. 29. HMM profile of CG10602 aligned against chain X of 3B7U, a template structure 
selected for modeling CG10602. 
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2. Validation 
The quality of the CG10602 model was evaluated using ProQ2 and ProSA, as described 
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score 
of -9.42). The ProSA per-residue energy score graph is also favorable, showing a score that is 
consistently negative over a window size of 40 residues, except for minor high-energy regions at 
the N-terminus and two loop regions. 
 
          
FIG. 30. Validation of the CG10602 model: ProQ2 quality score mapped to a 3D model of 
CG10602 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
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D. Structural Analyses 
A structural superposition reveals that the CG10602 model and human leukotriene 
hydrolase (3B7U) display a similar secondary structure architecture across the modeled region 
with substantial full-length overlap. The pairwise alignment generated by this structural 
superposition also indicates substantial conservation of residues having similar physiochemical 
properties. 
1. Secondary Structure 
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FIG. 31. Pairwise alignment of CG10602 and 3B7U generated from structural 
superposition with secondary structure elements and conserved residues highlighted. 
 
2. Physiochemical Properties 
 
 
 
FIG. 32. Pairwise alignment of CG10602 and 3B7U generated from structural 
superposition with conserved residues highlighted using the CLUSTALX color scheme. 
 
E. Analysis of Functional Residues 
LTA4H (PDB: 1H19) and CG10602 Model 
LTA4H Structure 
D. melanogaster 
Model 
Superimposed 
   
FIG. 33. LTA4H (3B7U, cyan-blue) superimposed on the predicted 
structure of CG10602 (green-red). RMSD: 0.891 Å. 
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LTA4H (PDB: 3B7U) and CG10602 Model Superimposed 
 
FIG. 34. LTA4H (3B7U, cyan-blue) superimposed on the predicted 
structure of CG10602 (green-red), with potential matches for conserved 
functional residues highlighted. 
 
 
F. Summary Table 
 
TABLE 6. Summary of features shared by LTA4H and potential D. melanogaster ortholog 
CG10602. 
 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
Leukotriene A4 
hydrolase 
(LTA4H, NP_000886.1, 
PDB: 1H19) 
611 
Peptidase family M1 
(PF01433) 
13-387 
 
LTA4H, C-term (PF09127) 
464-608 
H296, E297, H300, 
E319, D376 and 
Y384 
44% ID 
58% SIM 
  0.891 Å 
Uncharacterized protein 
(CG10602, 
NP_724139.1) 
613 
Peptidase family M1 
(PF01433) 
8-420 
 
LTA4H, C-term (PF09127) 
464-610 
H293, E294, H297, 
E316, D374 and 
Y382 
 
44 
 
GGT1 
The fifth gene in this set, CG6461, encodes a 579 amino acid protein (“Gamma-
glutamyltranspeptidase,” NP_573303.1) that shares 39% identity and 54% similarity to human 
Gamma-glutamyltranspeptidase 1 (GGT1, NP_001275762.1). GGT1 cleaves the gamma-
glutamyl bond of extracellular glutathione (gamma-Glu-Cys-Gly), glutathione conjugates, and 
other gamma-glutamyl compounds. With respect to eicosanoid synthesis, GGT1 catalyzes the 
conversion of leukotriene C4 (LTC4) to leukotriene D4 (LTD4). GGT1 operates as a 
heterodimer consisting of small and large subunits which are produced from the same precursor 
that undergoes autocatalytic cleavage to produce the mature form of the enzyme. The only 
reported catalytic residue is T381, which corresponds to T382 in CG6461. GGT1 residues R107, 
T399 and E420 are believed to play a role in glutamate binding [94]. CG6461 possesses putative 
analogs for each of these residues, namely R107, T400 and E421, respectively. CG6461 and 
GGT1 also share identical domain architecture, with Gamma-glutamyltranspeptidase (PF01019) 
domains spanning the majority of each protein. Superimposed, the human structure (4GDX) and 
CG6461’s predicted structure display an RMSD of 1.126 Å. 
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A. Predicted Secondary Structure 
 
 
FIG. 35. Predicted secondary structure of GGT1 and CG6461 calculated using 
PROMALS3D. 
 
46 
 
 
B. Domain Architecture 
 
FIG. 36. Predicted domain architecture of GGT1 and CG6461 determined using Interpro 
and Pfam. 
 
C. Model Generation and Validation 
 
1. Generation 
 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling 
CG6461. All three tools identify chains A and B of 4GDX (human gamma-
glutamyltranspeptidase 1 heavy and light chains, respectively) as high-scoring matches suitable 
for composite modeling. Human gamma-glutamyltranspeptidase 1 is expressed as a single 
polypeptide which is cleaved during post-translational processing to produce a heavy chain and a 
light chain which form the GGT1 holoenzyme complex. Chains A and B of the 4GDX PDB were 
joined using Chimera to form a single composite structure which was then used as a single 
template to model CG6461. 
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CG6461 Range Template Range % Identity % Similarity E-Value 
7-370 3-369 (Chain A) 44% 59% 7.0e-69 
 
378-548 3-170 (Chain B) 52% 71% 1.6e-47 
 
 
 
FIG. 37. HMM profile of CG6461 aligned against chains A and B of 4GDX, a template 
structure selected for modeling CG6461. 
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2. Validation 
 
The quality of the CG6461 model was evaluated using ProQ2 and ProSA, as described 
above in the discussion of CG10602. Again, overall model quality is high (a ProSA global Z-
score of -9.54). The ProSA per-residue energy score graph is also favorable, showing a score that 
is consistently negative over a window size of 40 residues. 
 
          
FIG. 38. Validation of the CG6461 model: ProQ2 quality score mapped to a 3D model of 
CG6461 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
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D. Structural Analyses 
A structural superposition reveals that the CG6461 model and human gamma-
glutamyltranspeptidase 1 (4GDX) display a similar secondary structure architecture across the 
modeled region with substantial full-length overlap. The pairwise alignment generated by this 
structural superposition also indicates substantial conservation of residues having similar 
physiochemical properties. 
1. Secondary Structure 
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FIG. 39. Pairwise alignment of CG6461 and 4GDX generated from structural 
superposition with secondary structure elements and conserved residues highlighted. 
 
2. Physiochemical Properties 
 
 
 
FIG. 40. Pairwise alignment of CG6461 and 4GDX generated from structural 
superposition with conserved residues highlighted using the CLUSTALX color scheme. 
 
E. Analysis of Functional Residues 
GGT1 (PDB: 4GDX) and CG6461 Model 
GGT1 Structure 
D. melanogaster 
Model 
Superimposed 
    
FIG. 41. GGT1 (4GDX, cyan-blue) superimposed on the predicted structure of 
CG6461 (green-red). RMSD: 1.126 Å. 
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GGT1 (PDB: 4GDX) and CG6461 Model Superimposed 
 
FIG. 42. GGT1 (4GDX, cyan-blue) superimposed on the predicted structure 
of CG6461 (green-red), with potential matches for conserved functional 
residues highlighted.  
 
 
F. Summary Table 
 
TABLE 7. Summary of features shared by GGT1 and potential D. melanogaster ortholog 
CG6461. 
 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
Gamma-
glutamyltranspeptidase 1 
(GGT1, NP_001275762.1, 
PDB: 4GDX) 
569 
Gamma-
glutamyltranspeptidase 
(PF01019) 
55-564 
T381 
39% ID 
54% SIM 
 1.126 Å 
Gamma-
glutamyltranspeptidase 
(CG6461, NP_573303.1) 
579 
Gamma-
glutamyltranspeptidase 
(PF01019) 
56-566 
T382 
 
DPEP1 
The sixth gene in this set, CG6154 (“DPEP,” NP_733146.2), encodes a 434 amino acid 
metallopeptidase that shares 42% identity and 56% similarity with human DPEP1 (“Dipeptidase, 
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renal,” NP_004404.1). Both enzymes contain a single Membrane dipeptidase (PF01244) domain 
spanning the majority of the protein. DPEP1 is known to regulate leukotriene activity by 
catalyzing the conversion of leukotriene D4 (LTD4) to leukotriene E4 (LTE4) using zinc as a 
cofactor. To that end, the residues H36, D38, E141, H214 and H235 are reported to be essential 
for coordinating the zinc ions required for catalysis. Aligned against CG6154, these residues 
correspond to H71, D73, E184, H257 and H278. This high degree of similarity extends to the 
tertiary structure, as the superimposed structure of human DPEP1 (1ITQ) and the predicted 
structure of CG6154 display a RMSD of 0.523 Å. 
A. Predicted Secondary Structure 
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FIG. 43. Predicted secondary structure of DPEP1 and CG6154 calculated using 
PROMALS3D. 
 
B. Domain Architecture 
 
FIG. 44. Predicted domain architecture of DPEP1 and CG6154 determined using Interpro 
and Pfam. 
 
C. Model Generation and Validation 
 
1. Generation 
 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling 
CG6154. All three tools identify chain A of 1ITQ (human renal dipeptidase) as a high-scoring 
match suitable for single-template modeling. 
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CG6154 Range Template Range % Identity % Similarity E-Value 
53-425 2-361 50% 72% 1.5e-113 
 
 
FIG. 45. HMM profile of CG6154 aligned against chain A of 1ITQ, a template structure 
selected for modeling CG6154. 
 
2. Validation 
The quality of the CG6154 model was evaluated using ProQ2 and ProSA, as described 
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score 
of -7.99). The ProSA per-residue energy score graph is also favorable, showing a score that is 
consistently negative over a window size of 40 residues. 
55 
 
          
FIG. 46. Validation of the CG6154 model: ProQ2 quality score mapped to a 3D model of 
CG6154 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
 
D. Structural Analyses 
 
A structural superposition reveals that the CG6154 model and human renal dipeptidase 
(1ITQ) display a similar secondary structure architecture across the modeled region with 
substantial full-length overlap. The pairwise alignment generated by this structural superposition 
also indicates substantial conservation of residues having similar physiochemical properties. 
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1. Secondary Structure 
 
 
FIG. 47. Pairwise alignment of CG6154 and 1ITQ generated from structural superposition 
with shared secondary structure elements and conserved residues highlighted. 
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2. Physiochemical Properties 
 
 
 
FIG. 48. Pairwise alignment of CG6154 and 1ITQ generated from structural superposition 
with conserved residues highlighted using the CLUSTALX color scheme. 
 
E. Analysis of Functional Residues 
DPEP1 (PDB: 1ITQ) and CG6154 Model 
DPEP1 Structure 
D. melanogaster 
Model 
Superimposed 
   
 
FIG. 49. DPEP1 (1ITQ, cyan-blue) superimposed on the predicted structure of CG6154 
(green-red). RMSD: 0.523 Å. 
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DPEP1 (PDB: 1ITQ) and CG6154 Model Superimposed 
 
FIG. 50. DPEP1 (1ITQ, cyan-blue) superimposed on the predicted 
structure of CG6154 (green-red), with potential matches for conserved 
functional residues highlighted. 
 
 
F. Summary Table 
 
TABLE 8. Summary of features shared by DPEP1 and potential D. melanogaster ortholog 
CG6154. 
 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
Dipeptidase, renal (DPEP1, 
NP_004404.1, PDB: 1ITQ) 
411 
Membrane dipeptidase 
(PF01244) 
31-349 
H36, D38, E141, 
H214 and H235 
42% ID 
56% SIM 
  0.523 Å 
DPEP 
(CG6154, NP_733146.2) 
434 
Membrane dipeptidase 
(PF01244) 
66-393 
H71, D73, E184, 
H257 and H278 
 
GPX1 
The seventh gene in this set, CG12013 (“glutathione peroxidase,” NP_728870.1), 
encodes a 169 amino acid selenoprotein that is 32% identical and 44% similar to human GPX1 
(“glutathione peroxidase 1,” NP_000572.2). As part of the eicosanoid pathway, GPX-1 converts 
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the 12(S)-HPETE produced by lipoxygenase-12 (12-LOX) into 12(S)-HETE. GPX1 requires a 
selenocysteine residue (U49) for catalysis. CG12013’s amino acid sequence indicates that a 
cysteine residue is present at the corresponding position in this enzyme. However, this residue 
may in fact be a selenocysteine, as this substitution is unlikely to be detected by standard 
sequencing techniques. A structural alignment of human GPX1 (2F8A) and the predicted 
structure of CG12013 reveals an RMSD of 0.699 Å. 
A. Predicted Secondary Structure 
 
 
FIG. 51. Predicted secondary structure of GPX1 and CG12013 calculated using 
PROMALS3D. 
 
B. Domain Architecture 
 
 
FIG. 52. Predicted domain architecture of GPX1 and CG12013 determined using Interpro 
and Pfam. 
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C. Model Generation and Validation 
 
1. Generation 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling 
CG12013. All three tools identify chain A of 2F8A (human glutathione peroxidase 1) as a high-
scoring match suitable for single-template modeling. 
 
FIG. 53. HMM profile of CG12013 aligned against chain A of 2F8A, a template structure 
selected for modeling CG12013. 
 
2. Validation 
The quality of the CG12013 model was evaluated using ProQ2 and ProSA, as described 
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score 
of -7). The ProSA per-residue energy score graph is also favorable, showing a score that is 
consistently negative over a window size of 40 residues. 
CG12013 Range Template Range % Identity % Similarity E-Value 
7-122 20-140 39% 62% 2.3e-17 
 
131-169 168-206 49% 64% 9.7e-05 
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FIG. 54. Validation of the CG12013 model: ProQ2 quality score mapped to a 3D model of 
CG12013 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
 
D. Structural Analyses 
A structural superposition reveals that the CG12013 model and human glutathione 
peroxidase 1 (2F8A) display a similar secondary structure architecture across the modeled region 
with substantial full-length overlap. The pairwise alignment generated by this structural 
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superposition also indicates substantial conservation of residues having similar physiochemical 
properties. 
1. Secondary Structure 
 
 
FIG. 55. Pairwise alignment of CG12013 and 2F8A generated from structural 
superposition with shared secondary structure elements and conserved residues 
highlighted. 
 
2. Physiochemical Properties 
 
 
 
FIG. 56. Pairwise alignment of CG12013 and 2F8A generated from structural 
superposition with conserved residues highlighted using the CLUSTALX color scheme. 
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E. Analysis of Functional Residues 
GPX1 (PDB: 2F8A) and CG12013 Model 
GPX1 Structure 
D. melanogaster 
Model 
Superimposed 
   
FIG 57. GPX1 (2F8A, cyan-blue) superimposed on the predicted structure of CG12013 
(green-red). RMSD: 0.699 Å. 
 
GPX1 (PDB: 2F8A) and X Model Superimposed 
 
FIG. 58. GPX1 (2F8A, cyan-blue) superimposed on the predicted 
structure of CG12013 (green-red), with potential matches for conserved 
functional residues highlighted. 
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F. Summary Table 
 
TABLE 9. Summary of features shared by GPX1 and potential D. melanogaster ortholog 
CG12013. 
 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
Glutathione peroxidase 1 
(GPX1, NP_000572.2, 
PDB: 2F8A) 
203 
GSHPx (PF00255) 
16-130 
C49 
32% ID 
44% SIM 
  0.699Å 
Glutathione peroxidase 
(CG12013, NP_728870.1) 
169 
GSHPx (PF00255) 
13-122 
C45 
 
CPA1 
The eighth and final gene in this set, CG18585 (“CPA,” NP_609132.1) encodes a 422 
amino acid protein that is 34% identical and 54% similar to human CPA1 (“Carboxypeptidase 
A1,” NP_001859.1). CPA1 is a metallocarboxypeptidase that requires a zinc atom as a cofactor 
for catalysis. CPA1 has been shown to convert the potent leukotriene C4 (LTC4) to the less 
potent leukotriene F4 (LTF4) by hydrolysis of an amide bond, suggesting that CPA1 serves to 
reduce inflammation. The residues H179, E182, H306 and E380 are reportedly required for 
catalysis. These residues correspond to H178, E181, H305 and E382 in CPA. Aligned, the 
structure of human CPA1 (3FJU) and the predicted structure of CG18585 display an RMSD of 
0.753 Å. 
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A. Secondary Structure Prediction 
 
 
 
FIG. 59. Predicted secondary structure of CPA1 and CG18585 calculated using 
PROMALS3D. 
 
B. Domain Architecture 
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FIG. 60. Predicted domain architecture of CPA1 and CG18585 determined using Interpro 
and Pfam. 
C. Model Generation and Validation 
 
1. Generation 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling 
CG18585. All three tools identify chain A of 2V77 (human carboxypeptidase A1) as a high-
scoring match suitable for single-template modeling. Human carboxypeptidase A1 undergoes 
posttranslational processing, which results in cleavage of the N-terminal portion of the 
polypeptide spanning from position 1 to 110 (i.e., including a signal peptide spanning 1-16 and 
an activation peptide spanning 17-110). The mature form of the enzyme consists of the C-
terminal portion of the polypeptide (i.e., position 111-419). CG18585 is predicted to share a 
similar architecture, as the N-terminal regions aligns against the sequence of the human 
carboxypeptidase A1 activation peptide. The C-terminal region of CG18585 which appears to 
correspond to the sequence encoding mature human carboxypeptidase A1 was modeled for this 
study. 
CG18585 Range Template Range % Identity % Similarity E-Value 
114-417 4-305 40% 65% 3.8e-69 
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FIG. 61. HMM profile of CG18585 aligned against chain A of 2V77, a template structure 
selected for modeling CG18585. 
 
2. Validation 
The quality of the CG18585 model was evaluated using ProQ2 and ProSA, as described 
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score 
of -7.75). The ProSA per-residue energy score graph is also favorable, showing a score that is 
consistently negative over a window size of 40 residues.  
 
            
FIG. 62. Validation of the CG18585 model: ProQ2 quality score mapped to a 3D model of 
CG18585 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
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D. Structural Analyses 
 
1. Secondary Structure  
 
A structural superposition reveals that the CG18585 model and human carboxypeptidase 
A1 (2V77) display a similar secondary structure architecture across the modeled region with 
substantial full-length overlap. The pairwise alignment generated by this structural superposition 
also indicates substantial conservation of residues having similar physiochemical properties. 
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FIG. 63. Pairwise alignment of CG18585 and 2V77 generated from structural 
superposition with shared secondary structure elements and conserved residues 
highlighted. 
 
2. Physiochemical Properties 
 
 
FIG. 64. Pairwise alignment of CG18585 and 2V77 generated from structural 
superposition with conserved residues highlighted using the CLUSTALX color scheme. 
 
E. Analysis of Functional Residues 
CPA1 (PDB: 2V77) and CG18585 Model 
CPA1 Structure 
D. melanogaster 
Model 
Superimposed 
   
FIG. 65. Truncated CPA1 (2V77, cyan-blue) superimposed on the predicted structure of 
CG18585 (green-red). RMSD: 0.753 Å. 
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Truncated CPA1 (PDB: 2V77) and CG18585 Model Superimposed 
 
 
FIG. 66. Truncated CPA1 (2V77, cyan-blue) superimposed on the predicted 
structure of CG18585 (green-red), with potential matches for conserved 
functional residues highlighted. 
 
F. Summary Table 
 
TABLE 10. Summary of features shared by CPA1 and potential D. melanogaster ortholog 
CG18585. 
 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
Carboxypeptidase A1 
(CPA1, NP_001859.1, 
PDB: 3FJU) 
419 
Carboxypeptidase activation 
peptide (PF02244) 
26-100 
 
Zinc carboxypeptidase 
(PF00246) 
128-406 
H179, E182, H306 
and E380 
34% ID 
54% SIM 
  0.753 Å 
CPA (CG18585, 
NP_609132.1) 
422 
Carboxypeptidase activation 
peptide (PF02244) 
33-106 
 
Zinc carboxypeptidase 
(PF00246) 
128-408 
H178, E181, H305 
and E382 
71 
Group 2: The Midrange Candidates 
Five candidates were identified in the search based more on structural similarity than 
underlying sequence conservation.  Members of this set share 20-30% sequence identity with the 
human target, but share similarity at the fold level and possess at least one conserved functional 
residue. 
HPGDS 
The first gene in this set, CG8938 (GST-S1, NP_725653.1) encodes a 249 amino acid 
glutathione-S-transferase enzyme, which displays 27% identity and 43% similarity to human 
HPGDS, (“Hematopoietic Prostaglandin D synthase,” NP_055300.1). HPGDS, alternatively 
known as Prostaglandin-H2 D-isomerase, is a glutathione-requiring prostaglandin D synthase. 
HPGDS operates as a homodimer, which can optionally be activated by Ca2+ and Mg2+ to 
increase catalytic efficiency to 150% of the basal level [86]. Coordination of the metallic ion 
ligands is coordinated by D93, D96 and D97. CG8938 and GST-S1 share an identical domain 
architecture, with an N-terminal GST-N domain (PF02798) and a C-terminal GST-C domain 
(PF00043). Similarly, CG8938 possesses aligned matches for two of the three aspartic residues 
requires for enhanced catalytic activity, at positions D139 and D143 (corresponding to D93 and 
D97 in HPGDS). At the corresponding position aligned to D96, CG8938 instead has an 
asparagine (N142). However, mutagenesis studies by Inouie et al. have shown that a D to N 
substitution at this same position in HPGDS actually increases PGD2 synthesis [95]. In addition 
to this sequence-based evidence, superposition of the predicted CG8938 structure and human 
HPGDS (1IYI) reveals an RMSD of 1.045 Å. 
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A. Secondary Structure Prediction 
 
 
FIG. 67. Predicted secondary structure of HPGDS and CG8938 calculated using 
PROMALS3D. 
 
B. Domain Architecture 
 
FIG. 68. Predicted domain architecture of HPGDS and CG8938 determined using Interpro 
and Pfam. 
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C. Model Generation and Validation 
 
1. Generation 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling CG8938. 
All three tools identify chain A of 1IYH (human hematopoietic prostaglandin D synthase) as a 
high-scoring match suitable for single-template modeling. 
 
FIG. 69. HMM profile of CG8938 aligned against chain A of 1IYH, a template structure 
selected for modeling CG8938. 
 
2. Validation 
The quality of the CG8939 model was evaluated using ProQ2 and ProSA, as described 
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score 
of -6.16). The ProSA per-residue energy score graph is also favorable, showing a score that is 
consistently negative over a window size of 40 residues, after the initial N-terminal segment that 
was generated using ab initio methods. This proline rich N-terminal segment may include a 
signal peptide or other processing-related motif. 
CG8938 Range Template Range % Identity % Similarity E-Value 
49-248 2-197 36% 61% 7.9e-36 
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FIG. 70. Validation of the CG8938 model: ProQ2 quality score mapped to a 3D model of 
CG8938 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
 
D. Structural Analyses 
 
A structural superposition reveals that the CG8938 model and human hematopoietic 
prostaglandin D synthase (1IYH) display a similar secondary structure architecture across the 
modeled region with substantial full-length overlap. The pairwise alignment generated by this 
structural superposition also indicates substantial conservation of residues having similar 
physiochemical properties. 
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1. Secondary Structure 
 
 
FIG. 71. Pairwise alignment of CG8938 and 1IYH generated from structural superposition 
with shared secondary structure elements and conserved residues highlighted. 
 
2. Physiochemical Properties 
 
 
 
FIG. 72. Pairwise alignment of CG8938 and 1IYH generated from structural superposition 
with conserved residues highlighted using the CLUSTALX color scheme. 
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E. Analysis of Functional Residues 
TABLE 11. Summary of features shared by HPGDS and potential D. melanogaster 
ortholog CG8938. 
 
HPGDS (PDB: 1IYI) and CG8938 Model 
HPGDS Structure 
D. melanogaster 
Model 
Superimposed 
   
FIG. 73. HPGDS (1IYI, cyan-blue) superimposed on the predicted structure of CG8938 
(green-red). RMSD: 1.045 Å. 
 
HPGDS (PDB: 1IYI) and CG8938 Model Superimposed 
 
FIG. 74. HPGDS (1IYH, cyan-blue) superimposed on the predicted 
structure of CG8938 (green-red), with potential matches for conserved 
functional residues highlighted. 
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F. Summary Table 
 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
Hematopoietic 
Prostaglandin D 
synthase 
(HPGDS, NP_055300.1, 
PDB: 1IYI) 
160 
GST-N domain (PF02798) 
4-73 
GST-C domain (PF00043) 
81-185 
D93, D96, D97 
27% ID 
 
43% SIM 
1.045 Å 
Glutathione S 
transferase S1 (CG8938, 
NP_725653.1) 
184 
GST-N domain (PF02798) 
50-119 
GST-C domain (PF00043) 
141-235 
D139, D143, N142 
 
PTGES3 
The second gene in this set, CG16817 (NP_649925.1) encodes a 184 amino acid protein, 
which displays 24% identity and 40% similarity to human PTGES3 (“prostaglandin E synthase 
3,” NP_006592.3). In contrast to PTGES1 and PTGES2 discussed above, PTGES3 is a cytosolic 
protein. However, all three enzymes share the same catalytic function, i.e., oxidoreduction of 
prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2). PTGES3 and CG16817 share 
an identical domain architecture, with a CS Domain (PF04969) spanning the N-terminus to the 
middle of the protein. The C-terminal region of PTGES3 is notable for showing a compositional 
bias towards aspartic acid and glutamic acid residues in the range spanning 108 to 160. At this 
time, only one crystal structure for PTGES3 has been published (1EJF) and this structure is 
limited to a truncated version of the protein spanning residue 1 to 110, i.e., the acidic C-terminal 
region has not been crystalized. An alignment of PTGES3 and CG16817 shows that CG16817 
also displays a compositional bias towards acidic residues at its C-terminus, though it is unclear 
what role this serves in either protein. We were unable to generate a full-length model of 
CG16817 due to a lack of any suitable template structure for the C-terminal acidic region. 
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However, the truncated CG16817 model (residues 1 to 113) shows a RMSD of 0.823 Å 
compared to PTGES3. 
A. Secondary Structure Prediction 
 
 
 
FIG. 75. Predicted secondary structure of PTGES3 and CG16817 calculated using 
PROMALS3D. 
 
B. Domain Architecture 
 
 
FIG. 76. Predicted domain architecture of PTGES3 and CG16817 determined using 
Interpro and Pfam. 
 
C. Model Generation and Validation 
 
1. Generation 
 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling 
CG16817. All three tools identify chain A of 1EJF (human prostaglandin E synthase 3) as a 
high-scoring match suitable for single-template modeling of the first two-thirds of CG16817 
(i.e., the region spanning1-110), which includes the CS domain mapped to the segment spanning 
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10-85. The crystal structure of the acidic (E/D-rich) C-terminus of human prostaglandin E 
synthase 3 was not included in 1EJF and is currently unknown. Sequence analysis of CG16817 
reveals that a similar E/D-rich segment at the C-terminus of the polypeptide, providing further 
support for CG16817 being orthologous to or at least functionally similar to human 
prostaglandin E synthase 3. The modeled portion of CG17817 is predicted to be structured as a 
β-sandwich consisting of two sheets of anti-parallel β-strands, which matches the structure of the 
corresponding portion of human prostaglandin E synthase 3. Attempts to model the acidic C-
terminal segment using ab initio methods were unable to generate a high-confidence structure. It 
should be noted that this segment is predicted to be an intrinsically disordered region (e.g., as 
predicted by the IUPRed server, http://iupred.enzim.hu/). As a result, the present structural 
analysis of CG16817 is limited to the segment spanning 1-110 of the full-length polypeptide 
sequence. 
 
FIG. 77. HMM profile of CG16817 aligned against chain A of 1EJF, a template structure 
selected for modeling CG16817. 
 
2. Validation 
The quality of the CG16817 model was evaluated using ProQ2, and ProSA as described 
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score 
of -2.96). The ProSA per-residue energy score graph is also favorable, showing a score that is 
CG16817 Range Template Range % Identity % Similarity E-Value 
9-127 3-121 26% 46% 8.7e-10 
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consistently negative over a window size of 40 residues, except for the loop regions connecting 
the β-sandwich halves. As noted above, this model is truncated and excludes the acidic C-
terminus of CG16817, which may contribute to the tertiary structure of the full-length protein in 
a manner that is not accurately represented by the current model. However, the modeled structure 
has a reasonable quality score and appears to be structurally analogous to the crystalized portion 
of human prostaglandin E synthase 3, which is similarly truncated. 
 
          
FIG. 78. Validation of the CG16817 model: ProQ2 quality score mapped to a 3D model of 
CG16817 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
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D. Structural Analyses 
 
A structural superposition reveals that the CG16817 model and human prostaglandin E 
synthase 3 (1EJF) display a similar secondary structure architecture across the modeled region 
with substantial full-length overlap. The pairwise alignment generated by this structural 
superposition also indicates substantial conservation of residues having similar physiochemical 
properties. 
1. Secondary Structure 
 
 
FIG. 79. Pairwise alignment of CG16817 and 1EJF generated from structural 
superposition with shared secondary structure elements and conserved residues 
highlighted. 
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2. Physiochemical Properties 
 
 
 
FIG. 80. Pairwise alignment of CG16817 and 1EJF generated from structural 
superposition with conserved residues highlighted using the CLUSTALX color scheme. 
 
E. Analysis of Functional Residues 
PTGES3 (PDB: 1EJF) and CG16817 Model (Partial) 
Truncated 
PTGES3 Structure 
D. melanogaster 
Model (Partial) 
Superimposed 
   
FIG. 81. Truncated PTGES3 (1EJF, cyan-blue) superimposed on 
the predicted structure of CG16817 (green-red). RMSD: 0.823 Å. 
 
PTGES3 (PDB: 1EJF) and CG16817 Model (Partial)  Superimposed 
 
 
FIG. 82. Truncated PTGES3 (1EJF, cyan-blue) superimposed on the predicted 
structure of CG16817 (green-red), with potential matches for conserved 
functional residues highlighted. 
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F. Summary Table 
 
TABLE 12. Summary of features shared by PTGES3 and potential D. melanogaster 
ortholog CG16817. 
 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
Prostaglandin E synthase 3 
(PTGES3, NP_006592.3, 
PDB: 1EJF) 
160 
CS Domain (PF04969) 
4-79 
N/A 
24% ID 
40% SIM 
0.823 Å 
Uncharacterized protein 
(CG16817, NP_649925.1) 
184 
CS Domain (PF04969) 
10-85 
N/A 
 
CBR1 
The third gene in this set, CG11200 (“CBR,” NP_611471.1) encodes a 355 amino acid 
protein that displays 20% identity and 33% similarity to human CBR1 (“carbonyl reductase 1,” 
NP_001748.1). CBR1 is a NADPH-dependent reductase with broad substrate specificity, e.g., it 
can convert PGE2 to PGF2α. It has been reported that CBR1 binds to NADP via N90 and that 
Y194 serves as a proton acceptor for the reaction. A corresponding match for both of these 
residues can be found in CG11200 at positions N154 and Y233. An alignment of human CBR1 
(3BHJ) against the predicted model for CG11200 shows an RMSD of 1.153 Å. 
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A. Secondary Structure Prediction 
 
 
 
FIG. 83. Predicted secondary structure of CBR1 and CG11200 calculated using 
PROMALS3D. 
 
B. Domain Architecture 
 
FIG. 84. Predicted domain architecture of CBR1 and CG11200 determined using Interpro 
and Pfam. 
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C. Model Generation and Validation 
 
1. Generation 
 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling 
CG11200. All three tools identify chain A of 3BHJ (human carbonyl reductase 1 complexed with 
glutathione) as a high-scoring match suitable for single-template modeling. 
 
FIG. 85. HMM profile of CG11200 aligned against chain A of 3BHJ, a template structure 
selected for modeling CG11200. 
 
2. Validation 
The quality of the CG11200 model was evaluated using ProQ2 and ProSA, as described 
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score 
of -6.55). The ProSA per-residue energy score graph is also favorable, showing a score that is 
consistently negative over a window size of 40 residues, except for the N-terminus (which is 
predicted to be a signal peptide) and a single loop region. 
CG11200 Range Template Range % Identity % Similarity E-Value 
68-206 5-143 34% 56% 1.6e-12 
 
224-317 184-269 34% 59% 1.6e-12 
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FIG. 86. Validation of the CG11200 model: ProQ2 quality score mapped to a 3D model of 
CG11200 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
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D. Structural Analyses 
 
1. Secondary Structure 
 
 
 
FIG. 87. Pairwise alignment of CG11200 and 3BHJ generated from structural 
superposition with secondary structure elements and conserved residues highlighted. 
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2. Physiochemical Properties 
 
 
 
FIG. 88. Pairwise alignment of CG11200 and 3BHJ generated from structural 
superposition with conserved residues highlighted using the CLUSTALX color scheme. 
 
E. Analysis of Functional Residues 
CBR1 (PDB: 3BHJ) and CG11200 Model 
CBR1 Structure 
D. melanogaster 
Model 
Superimposed 
   
FIG 89. CBR1 (3BHJ, cyan-blue) superimposed on the predicted structure of CG11200 
(green-red). RMSD: 1.153 Å. 
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CBR1 (PDB: 3BHJ) and CG11200 Model Superimposed 
 
FIG. 90. CBR1 (3BHJ, cyan-blue) superimposed on the predicted 
structure of CG11200 (green-red), with potential matches for conserved 
functional residues highlighted. 
 
 
F. Summary Table 
 
TABLE 13. Summary of features shared by CBR1 and potential D. melanogaster ortholog 
CG11200. 
 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
Carbonyl reductase 1 
(CBR1, NP_001748.1, 
PDB: 3BHJ) 
277 
Short chain dehydrogenase 
domain (PF16152) 
6-151 
N90 and Y194 
20% ID 
33% SIM 
1.153 Å 
CBR (CG11200, 
NP_611471.1) 
355 
Short chain dehydrogenase 
domain (PF16152) 
68-252 
N154 and Y233 
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HPGD 
The fourth gene in this set, CG18814 (NP_652673.2), encodes a 267 amino acid protein 
that displays 26% identity and 47% similarity to human HPGD (“15-hydroxyprostaglandin 
dehydrogenase NAD(+),” NP_000851.2). HPGD catalyzes the conversion of the 15-hydroxyl 
group of prostaglandins into a keto group, which strongly reduces the biologic activity of these 
molecules. As a result, HPGD is considered the primary enzyme responsible for degradation of 
prostaglandins. It has been reported that N91, S138, Q148 and Y151 are required for catalysis. 
[96]. CG18814 residues N89, S137 and Y150 of CG18814 align with these catalytic residues and 
are oriented at overlapping or directly adjacent positions in close proximity in the structural 
alignment of the CG18814 model against the structure of HPGD. CG18814 lacks an obvious 
analog for Q148, which is located in a flexible loop region. However, CG18814 possesses a 
structurally-aligned loop region which contains Q142. Q148 and Q142 are located within 
approximately 5Å of each other and oriented similarly in a static superposition of the predicted 
model and crystal structure and may be functionally analogous. Moreover, both proteins have an 
identical domain architecture, with a Short-chain dehydrogenase domain (PF00106) spanning 
from the N-terminus to approximately residue 180. Superposition of human HPGD (2GDZ) and 
the predicted structure of CG18814 reveals an RMSD of 0.715 Å. 
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A. Secondary Structure Prediction 
 
 
FIG. 91. Predicted secondary structure of HPGD and CG18814 calculated using 
PROMALS3D. 
 
B. Domain Architecture 
 
FIG. 92. Predicted domain architecture of HPGD and CG18814 determined using Interpro 
and Pfam. 
 
C. Model Generation and Validation 
 
1. Generation 
 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling 
CG18814. All three tools identify chain A of 2GDZ (human 15-hydroxyprostaglandin 
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dehydrogenase 1 complexed with NAD+) as a high-scoring match suitable for single-template 
modeling. 
 
FIG. 93. HMM profile of CG18814 aligned against chain A of 2GDZ, a template structure 
selected for modeling CG18814. 
 
2. Validation 
The quality of the CG18814 model was evaluated using ProQ2 and ProSA, as described 
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score 
of -6.94). The ProSA per-residue energy score graph is also favorable, showing a score that is 
consistently negative over a window size of 40 residues, except for the putative active site and a 
C-terminal loop. 
CG18814 Range Template Range % Identity % Similarity E-Value 
4-242 6-249 31% 59% 1.3e-34 
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FIG. 94. Validation of the CG18814 model: ProQ2 quality score mapped to a 3D model of 
CG18814 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
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D. Structural Analyses 
 
1. Secondary Structure 
 
 
 
FIG. 95. Pairwise alignment of CG18814 and 2GDZ generated from structural 
superposition with CG18814 with shared secondary structure elements and conserved 
residues highlighted. 
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2. Physiochemical Properties  
 
 
 
FIG. 96. Pairwise alignment of CG18814 and 2GDZ generated from structural 
superposition with conserved residues highlighted using the CLUSTALX color scheme. 
 
E. Analysis of Functional Residues 
HPGD (PDB: 2GDZ) and CG18814 Model 
HPGD Structure 
D. melanogaster 
Model 
Superimposed 
   
FIG. 97. HPGD (2GDZ, cyan-blue) superimposed on the predicted 
structure of CG18814 (green-red). RMSD: 0.715 Å. 
 
HPGD (PDB: 2GDZ) and CG18814 Model Superimposed 
 
FIG. 98. HPGD (2GDZ, cyan-blue) superimposed on the predicted 
structure of CG18814 (green-red), with potential matches for conserved 
functional residues highlighted. 
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F. Summary Table 
 
TABLE 14. Summary of features shared by HPGD and potential D. melanogaster ortholog 
CG18814. 
 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
15-hydroxyprostaglandin 
dehydrogenase NAD(+) 
(HPGD, NP_000851.2, 
 PDB: 2GDZ) 
266 
Short chain 
dehydrogenase domain 
(PF00106) 
6-170 
Y151 
26% ID 
47% SIM 
0.715 Å 
Uncharacterized protein 
(CG18814, NP_652673.2) 
267 
Short chain 
dehydrogenase domain 
(PF00106) 
7-166 
Y150 
 
TBXAS1 
The fifth and final gene in this set, CG3616 (“CYP450-9c1,” NP_523850.1) encodes a 
cytochrome p450 oxidase, which displays 27% identity and 45% similarity to TBXAS1 
(“thromboxane A synthase,” NP_001052.2). TBXAS1 localizes to the endoplasmic reticulum 
membrane, where it catalyzes the conversion of PGH2 to thromboxane A2 (TBA2). TBXAS1 is 
categorized as a cytochrome p450 family (CYP450) enzyme based on sequence similarity. This 
categorization is illustrated by the fact that the only pfam domain identified in TBXAS1 has a 
Cytochrome P450 domain (PF00067) spanning the majority of the protein. CYP450 enzymes are 
highly conserved in eukaryotes, where they catalyze many reactions involved in drug 
metabolism and synthesis of cholesterol, steroids and other lipids. However, this ubiquitous 
nature of CYP450 enzymes makes it difficult to identify potential orthologs for any one specific 
enzyme within the family. CG3616 was selected as a candidate from the set of eight candidates 
with similar sequences after taking into account the initial sequence comparison, the 
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transmembrane helix pattern (calculated using TOPCONS) and the alignment score against a 
multiple sequence alignment of known or high confidence TBXAS1 orthologs 
A. Secondary Structure Prediction 
 
 
FIG. 99. Predicted secondary structure of TBXAS1 and CG3616 calculated using 
PROMALS3D. 
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B. Domain Architecture 
 
FIG. 100. Predicted domain architecture of TBXAS1 and CG3616 determined using 
Interpro and Pfam. 
 
C. Model Generation and Validation 
 
1. Generation 
 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling 
CG3616. All three tools identify chain A of 4DGZ (human CYP450 3A4) as a high-scoring 
match suitable for single-template modeling. 
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CG3616 Range Template Range % Identity % Similarity E-Value 
17-519 2-476 33% 62% 2.8e-70 
 
 
FIG. 101. HMM profile of CG3616 aligned against chain A of 4DGZ, a template structure 
selected for modeling CG3616. 
 
2. Validation 
The quality of the CG3616 model was evaluated using ProQ2 and ProSA, as described 
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score 
of -8). The ProSA per-residue energy score graph is also favorable, showing a score that is 
consistently negative over a window size of 40 residues, except for the N-terminus which is 
predicted to be a signal peptide and a single loop region. 
100 
 
          
FIG. 102. Validation of the CG3616 model: ProQ2 quality score mapped to a 3D model of 
CG3616 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
 
D. Structural Analyses 
 
A crystal structure is currently unavailable for human thromboxane A synthase. 
However, based on sequence analysis this enzyme is predicted to display the typical CYP450 
fold and high quality models (based on CYP450 crystal strctures) are available. For example, a 
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high confidence model of human thromboxane A synthase is available from the SWISS MODEL 
database and was used in this study as a stand-in for the likely actual structure of human 
thromboxane A synthase. 
A structural superposition reveals that the CG3616 model and the predicted human 
thromboxane A synthase model display a similar secondary structure architecture across the 
modeled region with substantial full-length overlap. The most notable difference occurs at 
segment 282-304 of CG3616, which consists of a single short α-helix bordered by loops on 
either side (α-helix 14). The corresponding segment of the TBXAS1 model (286-325) consists of 
two α-helices joined by a short loop. The pairwise alignment generated by this structural 
superposition also indicates substantial conservation of residues having similar physiochemical 
properties. 
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1. Sequence Analysis 
 
 
FIG. 103. Pairwise alignment of CG3616 and 4DGZ generated from structural 
superposition with shared secondary structure elements and conserved residues 
highlighted. 
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2. Physiochemical Properties 
 
 
FIG. 104. Pairwise alignment of CG3616 and 4DGZ generated from structural 
superposition with conserved residues highlighted using the CLUSTALX color scheme. 
 
E. Analysis of Functional Residues 
TBXAS1 (SWISS-MODEL) and CG3616 Model 
TBXAS1 Model 
D. melanogaster 
Model 
Superimposed 
   
FIG. 105. TBXAS1 (SWISS-MODEL, cyan) superimposed on the predicted 
structure of CG3616 (green). RMSD: 0.699 Å. 
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TBXAS1 (SWISS-MODEL) and CG3616 Model Superimposed 
 
 
FIG. 106. TBXAS1 (4DGZ, cyan-blue) superimposed on the predicted 
structure of CG3616 (green-red), with potential matches for conserved 
functional residues highlighted. 
 
 
F. Summary Table 
 
TABLE 15. Summary of features shared by TBXAS1 and potential D. melanogaster 
ortholog CG3616. 
 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
Thromboxane A synthase 
(TBXAS1, NP_001052.2, 
PDB: N/A (modeled)) 
534 
Cytochrome P450 
domain (PF00067) 
44-530 
C479 
27% ID 
45% SIM 
0.699 Å 
Cytochrome P450-9c1 
(CG3616, NP_610820.1) 
518 
Cytochrome P450 
domain (PF00067) 
34-513 
C462 
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Group 3: The Most Distant Candidates 
Many of the putative orthologs identified in D. melanogaster although divergent in 
sequence from the human target, are similar enough that traditional methods for analyzing and 
aligning sequences can be utilized. However, for a small subset, the sequences are so divergent 
(i.e., 20-20% identical) that a more intensive analysis was required to determine whether further 
study was justified. 
PTGS1/PTGS2 
The search for a cyclooxygenase ortholog proved to be one of these difficult cases. As 
noted above, it is widely accepted that D. melanogaster lacks a cyclooxygenase ortholog. 
However, there have been sporadic reports of prostaglandin detected in D. melanogaster extracts 
over the years. The human genome encodes three major cyclooxygenase isozymes via two loci. 
PTGS1 encodes Cox-1 (a constitutive cyclooxygenase), whereas PTGS2 encodes Cox-2 (which 
is inducible and expressed in a tissue-specific manner) A truncated and poorly characterized 
isoform of PTGS1, Cox-3 is also known to be expressed in certain cells, and reportedly 
demonstrates reduced prostaglandin synthesis activity relative to COX-1 [97]. Cox-1 and Cox-2 
operate as homodimers and are characterized by two domains: an N-terminal EGF-like domain 
(IPR000742) and an animal heme peroxidase domain (PF03098). The former allows for 
association with the cell and nuclear membrane while the latter is responsible for the 
cyclooxygenase activity. The Cox enzymes initiate the prostaglandin synthesis pathway by 
converting arachidonic acid, or other polyunsaturated fatty acid (PUFA) substrates, into the 
unstable intermediate PGG2 followed by PGH2. During this process, it has been reported that a 
small amount of the PUFA substrate is converted into a racemic mixture of 15-
Hydroxyicosatetraenoic acids (i.e., 15-HETEs), which may be processed into lipoxins, a poorly 
understood class of anti-inflammatory eicosanoids. The Cox-1 and Cox-2 enzymes contains two 
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active sites: a heme with peroxidase activity, responsible for the reduction of PGG2 to PGH2, and 
a cyclooxygenase site, where arachidonic acid is converted into the hydroperoxy endoperoxide 
prostaglandin G2 (PGG2). Extensive studies have been performed on the sheep ortholog of Cox-
1, (NP_001009476.1; PDB: 1CQE), which is a proxy for the human ortholog [98]. These studies 
reveal that cyclooxygenase activity is mediated by Y385, which forms a radical capable of 
abstracting a hydrogen from the PUFA substrate (e.g., carbon-13 of arachidonic acid). H207 and 
H388 are also required for the dual peroxidase and cyclooxygenase functions performed by these 
enzymes [99, 100]. Other functional residues identified in the literature include R120, Q203, 
V349, and S530 [101]. R120 interacts with C-1 of the PUFA substrate, arachidonic acid [102]. 
Q203 is conserved among mammalian Cox enzymes, though the function of this residue is 
currently unknown. V349 is believed to play a role in substrate specificity; mammalian Cox 
enzymes share this residue and show a substrate preference for arachidonic acid, while 
invertebrate Cox enzymes that have a leucine at this position display specificity for linoleic acid 
[103]. and S530 acetylation is the basis for Cox-2 inhibition by aspirin [104]. 
An initial screen of D. melanogaster using BLASTP failed to identify meaningful hits. 
However, iterative HMMER searches were able to identify four potential candidates: CG4009 
(NP_650588.2), CG6969 (“Cardinal,” NP_651081.1), CG7660 (“Pxt,” NP_650648.3) and 
CG3477 (“Pxd,” NP_996223.1). Each of these candidates was added to a previously generated 
multiple sequence alignment containing PTGS1 and known or high confidence predicted 
orthologs using MAFFT.  The presence of absence of functional residues at or near aligned 
positions was noted. Similarly, the candidates were analyzed to determine the secondary 
structure and domain architecture of each protein. Following this filtering step, only two proteins 
remained as viable candidates for further study: CG4009 and CG6969. Both appear to have the 
requisite catalytic triad and share a similar domain architecture, though they each lack the N-
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terminal EGF-like domain. Notably, putative analogs for the H207, Y385 and H388 catalytic 
triad appear to be present on CG4009 at H163, Y399, H401 and on CG7660 at H222, Y564, 
H568, respectively. 
Structural models of CG4009 and CG6969, and CG7660 were built and validated as 
described above. PTGS1 (3N8V) and the predicted structure for CG4009 both display a 
cyclooxygenase fold, and the predicted catalytic domains are superimposable with a RMSD of 
1.875 Å. CG7660 and CG6969 each display a similar tertiary structure and with predicted 
catalytic domains that overlap with PTGS1 with a RMSD of 2.810 and 2.942 Å, respectively. 
The predicted structures differ from PTGS1at their N-terminus, which is expected given the 
absence of the EGF-like domain, though the CG4009 structure is marginally closer. In any event, 
these three structures present the necessary catalytic residues in a similar orientation as in PTGS1 
and so likely possess cyclooxygenase activity.  
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A. Secondary Structure Prediction 
 
 
 
FIG. 107. Predicted secondary structure of PTGS1 and CG4009 calculated using 
PROMALS3D. 
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B. Domain Architecture 
 
 
FIG. 108. Predicted domain architecture of PTGS1 and CG4009 determined using Interpro 
and Pfam. 
 
C. Model Generation and Validation 
 
1. Generation 
 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling 
CG4009. All three tools identified human COX-1 and COX-2, as well as the mouse and sheep 
orthologs, as potential templates for modeling a substantial portion of the animal haem 
peroxidase domain which spans 95-617 of CG4009 (e.g., 5F1A, 1IGZ). Lactoperoxidases, alpha-
dioxygenase and myeloperoxidase structures are also identified as templates for this portion of 
CG4009. However, none of these templates aligns well enough with CG4009 to support high 
confidence single-template modeling. As a result, I-TASSER was used to generate a multi-
template model of CG4009 based on six templates: 4HHR, 3FAQ, 3Q9K, 1CXP, 2GJ1, and 
1CVU. 
TABLE 16. Templates selected for compositing modeling of CG4009 using 
I-TASSER. 
 
Template Organism Protein % Identity Coverage 
4HHR A.thaliana 
Fatty acid 
dioxygenase 
20% 90% 
3FAQ B. bubalis Lactoperoxidase 30% 85% 
3Q9K B. taurus Lactoperoxidase 28% 85% 
1CXP Human Myeloperoxidase 29% 83% 
2GJ1 B. taurus Lactoperoxidase 28% 84% 
1CVU M. musculus COX-2 18% 76% 
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The multi-template alignment used by I-TASSER to generate a full-length model of 
CG4009 is shown below as Fig. 109. The full-length model is predicted to have a TM-SCORE of 
0.73±0.11. A TM-SCORE of >0.50 is typically indicative of a correct global fold assignment. 
This model was subjected to additional refinement (e.g., sidechain packing and loop refinement) 
as described in the methods section above. 
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FIG. 109. Multiple Sequence Alignment illustrating CG4009 aligned against template 
structures selected by I-TASSER for multi-template modeling of CG4009. 
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2. Validation 
The quality of the CG4009 model was evaluated using ProQ2 and ProSA, as described 
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score 
of -6.59). The ProSA per-residue energy score graph is also favorable, showing a score that is 
consistently negative over a window size of 40 residues except for loop regions and the N-
terminus, which is predicted to be a signal peptide. 
 
          
FIG. 110. Validation of the CG4009 model: ProQ2 quality score mapped to a 3D model of 
CG4009 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
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D. Structural Analyses 
 
A structural superposition reveals that the CG4009 model and the full-length structure of 
sheep COX-1 (3N8V) display a similar secondary structure architecture across the modeled 
region. Conserved secondary structure elements are readily apparent upon visual inspection of 
the superimposed structures, as illustrated by Fig. 113 below. However, the 3D position of many 
of these conserved secondary structure elements is shifted in three-dimensional space due to the 
alternative placement of intervening loop regions. Thus, while many analogous secondary 
structure elements are indeed present when the CG4009 model and COX-1 (3N8V) are 
superimposed, the conservation of these elements is not as clear from a pairwise structural 
alignment as is the case for many of the other enzymes analyzed in this study. 
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1. Secondary Structure 
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FIG. 111. Pairwise alignment of CG4009 and 3N8V generated from structural 
superposition with CG4009 with shared secondary structure elements and conserved 
residues highlighted. 
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2. Physiochemical Properties 
 
 
FIG. 112. Pairwise alignment of CG4009 and 3N8V generated from structural 
superposition with conserved residues highlighted using the CLUSTALX color scheme. 
 
E. Analysis of Functional Residues 
PTGS1 (PDB: 3N8V) and CG4009 Model 
PTGS1 Structure 
D. melanogaster 
Model 
Superimposed 
   
FIG. 113. PTGS1 (3N8V, cyan-blue) superimposed on the predicted structure of 
CG4009 (green-red). RMSD (predicted catalytic domain): 2.660 Å. 
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PTGS1 (PDB: 3N8V) and CG4009 Model Superimposed 
 
FIG. 114. PTGS1 (3N8V, cyan-blue) superimposed on the predicted 
structure of CG4009 (green-red), with potential matches for conserved 
functional residues highlighted. 
 
 
 
F. Summary Table 
 
TABLE 17. Templates selected by I-TASSER to model CG4009 using a composite 
modeling protocol. 
 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
Cyclooxygenase 1 
(PTGS1, NP_000953.2, 
PDB: 3N8V) 
599 
Animal heme peroxidase 
domain (PF03098) 
142-581 
H207, Y385 and 
H388 
14% ID 
26% SIM 
2.660 Å 
Uncharacterized protein 
(CG4009, NP_650588.2) 
649 
Animal heme peroxidase 
domain (PF03098) 
95-617 
H163, Y399, and 
H401 
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PTGDS 
The search for a potential ortholog for PTGDS also proved to be difficult. PTGDS is a 
second prostaglandin-D-synthase, which operates in conjunction with the isozyme HPGDS 
(discussed above). BLAST-based searching failed to identify any D. melanogaster candidates for 
this enzyme (i.e., an apparent ortholog for NP_000945.3). However, iterative HMMER searches 
suggested CG33126 (“NLaz,” NP_787960.1) merits further scrutiny despite having only 12% 
identity and 31% similarity to PTGDS. Both proteins share similar domain architecture, namely 
a Lipocalin (PF00061) domain, which is known to take the form of a beta barrel structure. A 
model was generated for PTGDS, as described above. Comparative studies revealed that human 
PTGDS (5WY9) and CG33126 overlap with an RMSD 2.084 Å and that CG33126 has an 
aligned match for PTGDS’s catalytic cysteine (C65) at position C67. CG33126 contains an N-
terminal alpha helix that is absent from PTGDS, however this can helix is predicted to be a 
signal peptide. PTGDS contains a similar N-terminal signal peptide that is cleaved during 
processing (i.e., omitted from the 5WY9 crystal structure). 
A. Secondary Structure Prediction 
 
 
 
FIG. 115. Predicted secondary structure of PTGDS and CG33126 calculated using 
PROMALS3D. 
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B. Domain Architecture 
 
FIG. 116. Predicted domain architecture of PTGDS and CG33126 determined using 
Interpro and Pfam. 
 
C. Model Generation and Validation 
 
1. Generation 
 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling 
CG33126. All three tools identify chain A of apolipoprotein D (2HZQ) and chain A of human 
prostaglandin D synthase (5WY9) as high-scoring matches suitable for single-template 
modeling. 2HZQ and 5WY9 are β-barrel proteins with a substantially similar tertiary structure. 
As a result, models generated using either template are substantially similar. For this study, 
5WY9 was selected as a template for modeling CG33126. 
CG33126 Range Template Range % Identity % Similarity E-Value 
34-184 26-178 18% 58% 5.0e-07 
 
 
 
FIG. 117. HMM profile of CG33126 aligned against chain A of 5WY9, a template structure 
selected for modeling CG33126. 
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2. Validation 
The quality of the CG33126 model was evaluated using ProQ2 and ProSA, as described 
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score 
of -5.47). The ProSA per-residue energy score graph is also favorable, showing a score that is 
largely negative over a window size of 40 residues. 
 
       
FIG. 118. Validation of the CG33126 model: ProQ2 quality score mapped to a 3D model of 
CG33126 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
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D. Structural Analyses 
 
A structural superposition reveals that the CG33126 model and human prostaglandin D 
synthase (5WY9) display a similar secondary structure architecture across the modeled region 
with substantial full-length overlap. The pairwise alignment generated by this structural 
superposition also indicates substantial conservation of residues having similar physiochemical 
properties. 
1. Secondary Structure 
 
FIG. 119. Pairwise alignment of CG33126 and 5WY9 generated from structural 
superposition with CG33126 with shared secondary structure elements and conserved 
residues highlighted. 
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2. Physiochemical Properties 
 
 
 
FIG. 200. Pairwise alignment of CG33126 and 5WY9 generated from structural 
superposition with conserved residues highlighted using the CLUSTALX color scheme. 
 
E. Analysis of Functional Residues 
PTGDS (PDB: 5WY9) and CG33126 Model 
PTGDS Structure 
D. melanogaster 
Model 
Superimposed 
   
FIG. 201. PTGDS (5WY9, cyan-blue) superimposed on the predicted structure of CG33126 
(green-red). RMSD: 2.084 Å. 
 
 
 
 
 
 
 
 
 
 
 
 
 
\ 
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PTGDS (PDB: 5WY9) and CG33126 Model Superimposed 
 
FIG. 202. PTGDS (5WY9, cyan-blue) superimposed on the predicted 
structure of CG33126 (green-red), with potential matches for conserved 
functional residues highlighted. 
 
 
F. Summary Table 
 
TABLE 18. Summary of features shared by PTGDS and potential D. melanogaster ortholog 
CG33126. 
 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
Prostaglandin-D-synthase 
(PTGDS, NP_000945.3, 
PDB: 5WY9) 
190 
Lipocalin domain 
(PF00061) 
40-184 
C65 
12% ID 
 
31% SIM 
2.084 Å 
Neural Lazarillo 
(CG33126, NP_787960.1) 
224 
Lipocalin domain 
(PF00061) 
48-190 
C67 
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PTGIS 
PTGIS (“prostacyclin synthase”) is another enzyme that does not have a clear ortholog in 
D. melanogaster. PTGIS catalyzes the isomerization of PGH2 to prostacyclin, the only 
prostaglandin with a bicyclic ring structure. PTGIS encodes a 500 amino acid enzyme 
characterized by a cytochrome p450 family domain ranging from position 30 to 494. The N-
terminus is predicted to contain a 200 amino acid signal sequence. BLAST and iterative 
HMMER searches reveal multiple high-scoring full length matches among the various CYP450 
enzymes encoded in the D. melanogaster genome. However, CG3466 (“CYP450-4d2,” 
NP_525043.1) was identified as the top candidate based upon similarity of its secondary 
structure profile. CG3466 possesses an aligned match for PTGIS’s heme axial ligand (C441) at 
position C449. PTGIS (2IAG) and CG3466 are superimposable with an RMSD of 1.213 Å, 
despite sharing only 14% identity and 30% similarity at the sequence level. 
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A. Secondary Structure Prediction 
 
 
FIG. 203. Predicted secondary structure of PTGIS and CG3466 calculated using 
PROMALS3D. 
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B. Domain Architecture 
 
FIG. 204. Predicted domain architecture of PTGIS and CG3466 determined using Interpro 
and Pfam. 
 
C. Model Generation and Validation 
 
1. Generation 
 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling 
CG3466. All three tools identify various CYP450 structures as suitable for high confidence 
single-template modeling of full-length CG3466. Chain A of human CYP450 3A4 (4DGZ) was a 
particularly high-scoring match and selected as a template for generating a model of CG3466 for 
this study. Human prostacyclin synthase (2IAG), which is also a member of the CYP450 
superfamily, was identified as a template. However, it was indicated as having a lower quality 
score for full-length modeling of this target and so was not selected as a template. 
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CG3466 Range Template Range % Identity % Similarity E-Value 
31-475 18-448 32% 57% 3.5e-59 
 
 
FIG. 205. HMM profile of CG3466 aligned against chain A of 4DGZ, a template structure 
selected for modeling CG3466. 
 
2. Validation 
The quality of the CG3466 model was evaluated using ProQ2 and ProSA, as described 
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score 
of -8.59). The ProSA per-residue energy score graph is also favorable, showing a score that is 
substantially negative over a window size of 40 residues except for in a single loop region. 
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FIG. 206. Validation of the CG3466 model: ProQ2 quality score mapped to a 3D model of 
CG3466 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
 
D. Structural Analyses 
 
A structural superposition reveals that the CG3466 model and human prostacyclin 
synthase (2IAG) display a similar secondary structure architecture across the modeled region 
with substantial full-length overlap. The pairwise alignment generated by this structural 
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superposition also indicates substantial conservation of residues having similar physiochemical 
properties. 
1. Secondary Structure 
 
 
FIG. 207. Pairwise alignment of CG3466 and 2IAG generated from structural 
superposition with secondary structure elements and conserved residues highlighted. 
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2. Physiochemical Properties 
 
 
 
FIG. 208. Pairwise alignment of CG3466 and 2IAG generated from structural 
superposition with conserved residues highlighted using the CLUSTALX color scheme. 
 
E. Analysis of Functional Residues 
PTGIS (PDB: 2IAG) and CG3466 Model 
PTGIS Structure 
D. melanogaster 
Model 
Superimposed 
   
FIG. 209. PTGIS (2IAG, cyan-blue) superimposed on the predicted structure of 
CG3466 (green-red). RMSD: 1.213 Å. 
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PTGIS (PDB: 2IAG) and CG3466 Model Superimposed 
 
FIG. 210. PTGIS (2IAG, cyan-blue) superimposed on the predicted 
structure of CG3466 (green-red), with potential matches for conserved 
functional residues highlighted. 
 
 
F. Summary Table 
 
TABLE 19. Summary of features shared by PTGIS and potential D. melanogaster ortholog 
CG3466. 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
Prostacyclin synthase 
(PTGIS, NP_000952.1, 
PDB: 2IAG) 
500 
Cytochrome p450 family 
(PF00067) 
30-494 
C441 
14% ID 
30% SIM 
1.213 Å 
Cytochrome p450-4d2 
(CG3466, NP_525043.1) 
501 
Cytochrome p450 family 
(PF00067) 
31-495 
C449 
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LTC4S 
Leukotriene C4 synthase (LTC4S), is a 150 amino acid enzyme that catalyzes the 
conjugation of leukotriene A4 with reduced glutathione to form leukotriene C4. BLAST searches 
against D. melanogaster fail to identify an obvious ortholog. However, an iterative HMMER 
search identified the 165 amino acid protein CG33178 (NP_788904.1) as a potential candidate. 
The two proteins share full length identity pf 18% and similarity of 31% and have an identical 
domain architecture in the form of a single MAPEG domain (PF01124) spanning the bulk of the 
protein. Studies of the crystal structure of LTC4S (2PNO) have revealed that it is an integral 
membrane protein composed of four transmembrane helices and that it functions as a 
homotrimer. The predicted model of CG33178 displays a similar fold, consisting of a bundle of 
four alpha helices, and it superimposes on 2PNO with an RMSD of 1.257 Å. CG33178 also 
displays potential equivalents for each of LTC4S’s catalytically relevant residues (R30, R31 and 
R104) at positions R51, R53 and R139. 
A. Secondary Structure Prediction 
 
 
 
FIG. 211. Predicted secondary structure of LTC4S and CG33178 calculated using 
PROMALS3D. 
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B. Domain Architecture 
 
 
FIG. 212. Predicted domain architecture of LTC4S and CG33178 determined using 
Interpro and Pfam. 
 
C. Model Generation and Validation 
 
1. Generation 
 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling 
CG33178. All three tools identify chain A of 2H8A (R. norvegicus Microsomal Glutathione S-
transferase 1) as a high-scoring match suitable for single-template modeling. Human leukotriene 
C4 synthase is also identified as a potential template, but has a lower full-length alignment score. 
CG33178 Range Template Range % Identity % Similarity E-Value 
21-155 7-145 42% 64% 1.0e-24 
 
 
 
FIG. 213. HMM profile of CG33178 aligned against chain A of 2H8A, a template structure 
selected for modeling CG33178. 
 
2. Validation 
The quality of the CG33178 model was evaluated using ProQ2 and ProSA, as described 
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score 
134 
of -4.04). The ProSA per-residue energy score graph is also favorable, showing a score that is 
consistently negative over a window size of 40 residues except for a single loop region. 
 
          
FIG. 214. Validation of the CG33178 model: ProQ2 quality score mapped to a 3D model of 
CG33178 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
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D. Structural Analyses 
 
A structural superposition reveals that the CG33178 model and human leukotriene C4 
synthase (2PNO) display a similar secondary structure architecture across the modeled region 
with substantial full-length overlap. The pairwise alignment generated by this structural 
superposition also indicates substantial conservation of residues having similar physiochemical 
properties. 
1. Secondary Structure 
 
 
FIG. 215. Pairwise alignment of CG33178 and 2PNO generated from structural 
superposition with shared secondary structure elements and conserved residues 
highlighted. 
 
2. Physiochemical Properties 
 
 
 
FIG. 216. Pairwise alignment of CG33178 and 2PNO generated from structural 
superposition with conserved residues highlighted using the CLUSTALX color scheme. 
136 
E. Analysis of Functional Residues 
LTC4S (PDB: 2PNO) and CG33178 Model 
LTC4S Structure 
D. melanogaster 
Model 
Superimposed 
   
FIG. 217. LTC4S (2PNO, red) superimposed on the predicted 
structure of CG33178 (green). RMSD: 1.257 Å. 
 
LTC4S (PDB: 2PNO) and CG33178 Model Superimposed 
 
FIG. 218. LTC4S (2PNO, cyan-blue) superimposed on the predicted 
structure of CG33178 (green-red), with potential matches for conserved 
functional residues highlighted. 
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F. Summary Table 
 
TABLE 20. Summary of features shared by LTC4S and potential D. melanogaster ortholog 
CG33178. 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
Leukotriene C4 synthase 
(LTC4S, NP_665874.1, 
PDB: 2PNO) 
150 
MAPEG domain 
(PF01124) 
8-131 
R30, R31 and R104 
18% ID 
31% SIM 
1.257 Å 
Uncharacterized protein 
(CG33178, NP_788904.1) 
165 
MAPEG domain 
(PF01124) 
29-159 
R51, R53 and R139 
 
ALOX5AP 
Arachidonate 5-lipoxygenase-activating protein (ALOX5AP, NP_001620.2), the final 
target protein in this set, is required for leukotriene synthesis by arachidonate 5-lipoxygenase 
(ALOX5). It has been reported that ALOX5AP functions by binding ALOX5 to the membrane 
and loading polyunsaturated fatty acid substrates (e.g., arachidonic acid) onto ALOX5 for 
conversion into leukotriene A4. Like LTC4S above, ALOX5AP is a MAPEG family protein that 
functions as a membrane-associated homotrimer. BLAST searches for a potential ortholog do not 
identify a clear match in D. melanogaster, though iterative HMMER searches reveal CG33177 
and CG33178 as potential candidates. Both are MAPEG family proteins with highly similar 
sequences and predicted tertiary structures. CG33178 displays greater sequential similarity to 
LTC4S and analogs for the catalytically relevant residues and so was assigned as the top 
candidate for LTC4S. As a result, CG33177 was selected as the top candidate for a potential 
ortholog for ALOX5AP. The two proteins display 13% identity and 28% similarity and overlap 
with an RMSD of 1.024 Å.  
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A. Secondary Structure Prediction 
 
 
 
FIG. 219. Predicted secondary structure of ALOX5AP and CG33177 calculated using 
PROMALS3D. 
 
B. Domain Architecture 
 
FIG. 220. Predicted domain architecture of ALOX5AP and CG33177 determined using 
Interpro and Pfam. 
 
C. Model Generation and Validation 
 
1. Generation 
 
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling 
CG33177. All three tools identify chain A of 2H8A (R. norvegicus Microsomal Glutathione S-
transferase 1) as a high-scoring match suitable for single-template modeling. 
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CG33177 Range Template Range % Identity % Similarity E-Value 
23-156 8-144 44% 63% 7.8e-28 
 
 
 
FIG. 221. HMM profile of CG33177 aligned against chain A of 2H8A, a template structure 
selected for modeling CG33177. 
 
2. Validation 
The quality of the CG33177 model was evaluated using ProQ2 and ProSA, as described 
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score 
of -4.33). The ProSA per-residue energy score graph is also favorable, showing a score that is 
consistently negative over a window size of 40 residues, except for the flexible C-terminal α-
helix. 
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FIG. 222. Validation of the CG33177 model: ProQ2 quality score mapped to a 3D model of 
CG33177 (top); ProSA global quality score ranking (lower left) and per-residue quality 
graph (lower right). 
 
D. Structural Analyses 
A structural superposition reveals that the CG33177 model and human ALOX5AP 
(2Q7M) display a similar secondary structure architecture across the modeled region with full-
length overlap. The pairwise alignment generated by this structural superposition also indicates 
substantial conservation of residues having similar physiochemical properties. 
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1. Secondary Structure 
 
 
 
FIG. 223. Pairwise alignment of CG33177 and 2Q7M generated from structural 
superposition with shared secondary structure elements and conserved residues 
highlighted. 
 
2. Physiochemical Properties 
 
 
 
FIG. 224. Pairwise alignment of CG33177 and 2Q7M generated from structural 
superposition with conserved residues highlighted using the CLUSTALX color scheme. 
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E. Analysis of Functional Residues 
ALOX5AP (PDB: 2Q7M) and CG33177 Model 
ALOX5AP 
Structure 
D. melanogaster 
Model 
Superimposed 
 
 
  
FIG. 225. ALOX5AP (2Q7M, cyan) superimposed on the predicted 
structure of CG33177 (green). RMSD: 1.024 Å. 
 
ALOX5AP (PDB: 2Q7M) and CG33177 Model Superimposed 
 
FIG. 226. ALOX5AP (2Q7M, cyan-blue) superimposed on the predicted 
structure of CG33177 (green-red), with potential matches for conserved 
functional residues highlighted. 
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F. Summary Table 
 
TABLE 21. Summary of features shared by ALOX5AP and potential D. melanogaster 
ortholog CG33177. 
 
 
Length 
(AA) 
Domain 
Architecture 
(Pfam, range) 
Functional Residues 
(aligned matches in 
D. melanogaster) 
Sequence 
ID% 
Structural 
Overlap 
(RMSD) 
Arachidonate 5-lipoxygenase-
activating protein  
(ALOX5AP, NP_001620.2, 
PDB: 2Q7M) 
161 
MAPEG domain 
(PF01124) 
5-136 
N/A 
13% ID 
 
28% SIM 
1.024 Å 
Uncharacterized protein 
CG33177, NP_788903.1) 
167 
MAPEG domain 
(PF01124) 
30-161 
N/A 
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Chapter 4. Discussion 
Our results suggest that D. melanogaster may possess a set of eicosanoid synthesis 
enzymes similar to the canonical eicosanoid synthesis enzymes found in humans and mammals 
generally. At this stage, it is unknown whether these enzymes form a functional eicosanoid 
synthesis pathway similar to the mammalian pathway or if D. melanogaster possesses a unique 
eicosanoid synthesis pathway (e.g., structural differences in the D. melanogaster enzymes may 
result in the processing of different PUFA substrates and synthesis of alternative lipid mediators 
other than the canonical eicosanoids). Notwithstanding these caveats, a schematic of a putative 
D. melanogaster eicosanoid synthesis pathway based on our analysis is shown as Fig. 227 below. 
Notably, the proposed pathway appears to account for a full complement of prostaglandin 
synthesis enzymes. A functional thromboxane synthesis pathway may also be present, as 
potential orthologs for thromboxane A synthase have been identified. However, given the 
structural and sequential similarity of TBXA synthase to the numerous functionally unrelated 
cytochrome p450 oxidase in the D. melanogaster genome, speculation must be reserved pending 
experimental validation. The existence of a leukotriene synthesis arm of the pathway could not 
be fully resolved since a thorough search of the D. melanogaster genome has failed to identify a 
potential lipoxygenase, which is critical for the initial processing of the PUFA substrate into 
leukotriene intermediates. Interestingly, potential orthologs exist for each of the downstream 
leukotriene processing enzymes. Based upon our current understanding, a functional 
lipoxygenase is necessary for HETE intermediates and the corresponding final products (e.g., 
lipoxins and other non-canonical eicosanoids).  
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FIG 227. A theoretical D. melanogaster eicosanoid synthesis pathway. 
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Studies using conventional sequence analysis techniques alone have failed to demonstrate 
the possible existence of a functional eicosanoid synthesis pathway and these negative results 
suggested that flies do not possess the ability to synthesize eicosanoids [105, 106]. However, our 
data challenges this view and suggest that the fly genome may in fact possess potential orthologs 
for a majority of the eicosanoid synthesis enzymes. These candidates have thus far eluded 
detection because of the high degree of sequential divergence compared to the mammalian 
enzymes. However, when compared at the structural level it is clear that these candidates share 
the same overall fold and matches for the known or predicted catalytic residues. The existence of 
eicosanoid synthesis enzymes would partially explain recent studies that have identified 
prostaglandins or prostaglandin-like compounds in D. melanogaster when AA was provided in 
their diet [106-108]. However, questions remain as to the exact role played by these enzymes and 
the intermediate and final end products of the pathway. 
We speculate that the apparently missing lipoxygenase may be partially explained by D. 
melanogaster expressing a cyclooxygenase with lipoxygenase activity. Dual functional 
cyclooxygenases have been identified which are able to generate prostaglandins and 
lipoxygenase products (e.g. HPETEs). For example, mammalian cyclooxygenases have been 
shown to produce limited amounts of 11- and 15-HPETE as a by-product in addition to PGH, 
[109-112], and aspirin-acetylated COX-2 has been shown to produce 15R-HETEs [113]. Similar 
activity by one of the putative D. melanogaster COX orthologs could provide upstream 
processing needed for 11- and 15-HPETE, though this fails to provide the 5-HPETE intermediate 
needed for downstream leukotriene synthesis. Alternatively, 5-HETEs may be produced using an 
unconventional mechanism by the COX candidates or perhaps by an unidentified enzyme. The 
existence of structurally conserved downstream leukotriene synthesis enzymes suggests that the 
upstream intermediates are likely present in some form. D. melanogaster may possess a CYP450 
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enzyme capable of synthesizing 5-HETE; lipoxygenase-like CYP450s have been identified that 
produce 5-, 8-, 9-, 11-, 12- and 20-HETEs [114, 115]. Recent studies have reported on bacterial 
lipoxygenases which are highly divergent from animal and plant lipoxygenases, both in terms of 
overall sequence conservation and the presence of expected catalytic residues [116]. There is 
also a possibility that D. melanogaster expresses a functional 5-LOX that radically differs from 
the canonical profile of a lipoxygenase. 
The existence of a functional eicosanoid synthesis pathway requires both the presence of 
the requisite synthetic enzymes and suitable substrates. The mammalian eicosanoids are 
primarily derived from 20-carbon PUFAs (arachidonic acid, eicosapentaenoic acid and dihomo-
γ-linolenic acid), as well as from 18-carbon PUFAs (γ-linolenic acid, α-linolenic acid and 
linoleic acid). It has been reported that the D. melanogaster lacks homologs for the mammalian 
Δ5 and Δ6 desaturases based upon sequence analyses, and so it should be unable to synthesize 
20–22 carbon PUFAs from essential fatty acid precursors [117]. Studies by the same group have 
also shown that flies raised in the absence of 20-carbon PUFAs for several generations remain 
healthy, implying that 20-carbon PUFAs are non-essential [106]. Based on these findings it is 
generally accepted that D. melanogaster relies on PUFAs obtained from its vegetarian diet, 
which is generally limited to the essential 18-carbon fatty acids linoleic acid (18:2n-6) and α-
linolenic acid (18:3n-3). 
In the vertebrate pathway, the 18-carbon fatty acids linoleic acid and α-linolenic acid can 
be processed into the 20-carbon PUFAs arachidonic acid and eicosapentaenoic acid, 
respectively, via a three-step process. First, a double bond is removed by a Δ6 desaturase and 
then an elongase extends the PUFA chain by the addition of two carbons. Finally, a Δ5 
desaturase removes a double bond, completing the conversion. These 20-carbon PUFAs are then 
capable of being processed by COX or LOX to generate the canonical eicosanoids. 18-carbon 
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PUFAs (e.g., linoleic acid) may also be processed by 15-LOX into hydroxyoctadecadienoic acids 
(9- and 13-HODEs), a subfamily of non-canonical eicosanoids.  Based on the current 
understanding that D. melanogaster lacks Δ5 and Δ6 desaturase activity, it would be expected 
that the 18-carbon PUFAs obtained from its diet are processed into HODEs as opposed to 
eicosanoid derivatives of the 20-carbon PUFAs. Recent studies have validated this hypothesis, 
confirmed the presence of 9- and 13-HODEs in D. melanogaster extracts [118]. However, given 
the reports of prostaglandin-like molecules in D. melanogaster extracts, it is probable that 
additional lipid processing is taking place to produce compounds similar to the canonical 
eicosanoids. Contrary to the published literature, our HMMER-based sequence analysis of the D. 
melanogaster genome has identified a potential Δ5 and Δ6 desaturase which is not identified by 
typical BLAST searches. The uncharacterized genes CG17928 and CG13279 (NP_609810.1 and 
NP_477154.1, respectively) encode proteins with reasonable full-length alignment to the human 
Δ5 and Δ6 desaturase. These D. melanogaster proteins display domain architecture similar to the 
human enzymes and possess the critical His box 1, 2 and 3 motifs essential for desaturase 
activity [119]. Based on these findings, we suggest that D. melanogaster may in fact have a 
mechanism of converting C18 to C20 PUFAs. The existence of this functionality and the nature 
and extent of expression of these putative desaturases will need to be experimentally validated, 
though biochemical evidence may be difficult to obtain if expression is occurring at a low level 
or in a limited population of tissue. Most of the biochemical studies reporting prostaglandin-like 
compounds in D. melanogaster have identified these compounds in a limited subset of tissue 
(e.g., in reproductive tissue during oogenesis) [120].  However, based on our findings it appears 
that the existence of Δ5 and Δ6 desaturases cannot be conclusively ruled out at this time.  
The present study suggests that D. melanogaster has a set of eicosanoid synthesis 
enzymes, and in fact may possess a functional equivalent for the mammalian eicosanoid 
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synthesis pathway. Due to the limitations of traditional sequence analysis techniques we have 
explored advanced approaches to identify orthologs and demonstrate that structural models 
generated for several of these distant matches appear to display a high degree of structural 
similarity with members of the mammalian eicosanoid synthesis pathway and possess putative 
analogs for known functional residues. These initial findings, combined with other recent 
biochemical studies, suggest the possibility that D. melanogaster likely utilizes of eicosanoid 
signaling, raising the possibility that it may be useful as a model for the study of eicosanoid 
signaling and inflammation. Our studies with Drosophila, a system with low genetic redundancy 
and remarkable biological conservation will be highly relevant and transferrable to designing 
therapies for chronic disorders in humans. Our findings will also be relevant to the development 
of novel insect control measures.  
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